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Mycobacterium abscessus, a relative of Koch’s bacillus, has recently emerged for an 
increasing number of disease manifestations, ranging from pulmonary to skin infections. Its 
high intrinsic antibiotic resistance poses a significant threat and often leads to its persistence 
when other pathogens have been successfully eradicated by antimicrobial chemotherapy. 
Indeed, M. abscessus is naturally resistant, not only to the conventional first-line anti-
tuberculosis drugs, but also towards most major classes of antibiotics used for treatment of 
Gram
+
 and Gram
- 
bacterial infections, namely β-lactams, aminoglycosides and macrolides. 
This notoriety of M. abscessus has lately motivated several research groups worldwide to 
study this bacterium in order to decipher its antibiotic resistance mechanisms. 
 
M. abscessus genome analyses revealed various genes putatively involved in its innate 
rifamycin, aminoglycoside and β-lactam resistance. However, the exact function and the 
molecular role of these genes on the pathogen’s high degree of resistance remain under cover. 
As elucidation of drug resistance mechanisms, heavily relies on proper genetic manipulation 
and particularly, on generation of mutants by targeted gene inactivation, research attempts 
into M. abscessus were hampered by the limited number of available genetic tools. 
 
Aiming to investigate the molecular basis underlying rifamycin, aminoglycoside and β-lactam 
resistance in M. abscessus, we firstly established an apramycin positive selection
 
and a novel 
katG-dependent isoniazid counterselection strategy to generate deletion mutants of the 
putatively involved genes. Subsequently, we performed minimal inhibitory concentration 
(MIC) assays towards a variety of antimicrobial agents to determine the susceptibility level of 
the deletion mutants in comparison to the M. abscessus parental strain. 
 
This study identified (i) Arr_Mab, a rifampicin ADP-ribosyltransferase, which ribosylates and 
thereby inactivates rifampicin, as the major determinant of innate rifamycin resistance in M. 
abscessus; (ii) AAC(2') and Eis2, two acetyltransferases which transfer acetyl groups on 
crucial residues of aminoglycoside drugs leading to their inactivation, as two distinct 
aminoglycoside resistance determinants which confer M. abscessus clinically relevant drug 
resistance; and (iii) Bla_Mab, a broad-spectrum class A β-lactamase, which rapidly 
hydrolyses most β-lactam antibiotics except imipenem, meropenem and cefoxitin, as the 
major determinant of innate β-lactam resistance in M. abscessus. 
 
These findings build basic knowledge on M. abscessus intervention strategies and testify to 
the urgent need to develop novel compounds that can escape Arr_Mab-mediated rifamycin 
resistance, AAC(2')- and Eis2-mediated aminoglycoside resistance and Bla_Mab-mediated β-
lactam resistance of this highly resistant pathogen. 
ZUSAMMENFASSUNG 
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Mycobacterium abscessus ist in letzter Zeit immer öfter als Verursacher verschiedener 
Krankheitsbilder, von pulmonalen Erkrankungen bis hin zu Hautinfektionen, beschrieben 
worden. Seine hohe, intrinsische Antibiotikaresistenz stellt eine erhebliche Bedrohung dar, 
weil sie erheblich zur Persistenz des Erregers beiträgt. M. abscessus verfügt nicht nur über 
eine natürliche Resistenz gegenüber den konventionellen first-line Medikamenten gegen 
Tuberkulose, sondern auch gegenüber der Mehrheit der Antibiotika die zur Behandlung von 
Gram
+
 und Gram
-
 bakteriellen Infektionen eingesetzt werden, wie β-Laktamen, 
Aminoglykosiden und Makroliden. Diese Befunde haben jüngst weltweit Forschungsgruppen 
angeregt, M. abscessus zu studieren um die Mechanismen der Antibiotikaresistenz zu 
entschlüsseln.  
Genom-Untersuchungen von M. abscessus identifizierten verschiedene Gene die vermutlich 
an der intrinsischen Resistenz gegenüber Rifampicin, Aminoglykosiden und β-Laktamen 
beteiligt sind. Die genaue Funktion und molekulare Bedeutung dieser Gene, blieb jedoch 
bislang verborgen. Die Aufklärung von Resistenzmechanismen basiert auf der Verfügbarkeit 
von geeigneten genetischen Werkzeugen, die zur gezielten Generierung von 
Deletionsmutanten verwendet werden können. Aufgrund der geringen Anzahl verfügbarer 
genetischer Werkzeuge waren die Forschungsbestrebungen für M. abscessus eingeschränkt.  
Zur Untersuchung der molekularen Ursachen der Rifampicin-, Aminoglykosid- und β-
Laktamresistenz in M. abscessus, etablierten wir zuerst eine Apramycin Positivselektion und 
eine neue katG-abhängige Isoniazid Gegenselektion, um Deletions-Mutanten der vermeintlich 
beteiligten Gene zu generieren. Anschliessend führten wir Untersuchungen zu Minimalen 
Inhibitionskonzentrationen verschiedener antimikrobieller Substanzen durch, um die 
Antibiotikaempfindlichkeit der Deletionsmutanten mit der Empfindlichkeit des 
ursprünglichen Erregerstammes von M. abscessus zu vergleichen.  
Diese Arbeit identifizierte i) Arr_Mab, eine Rifampicin ADP-Ribosyltransferase, die 
Rifampicin eine Ribosylgruppe hinzufügt und es somit inaktiviert, als massgeblichen Faktor 
der intrinsischen Rifampicin Resistenz von M. abscessus; ii) AAC(2') und Eis2, zwei 
Acetyltransferasen, die Acetylgruppen an entscheidenden Resten von Aminoglykosiden 
anbringen und somit eine Antibiotika Inaktivierung hervorrufen, als zwei Aminoglykosid-
Resistenz Faktoren, die M. abscessus eine relevante, klinische Medikamentenresistenz 
verleihen; und iii) Bla_Mab, eine Breitspektrum-β-Laktamase der Klasse A, welche die 
meisten β-Laktam-Antibiotika effizient hydrolysiert, mit Ausnahme von Imipenem, 
ZUSAMMENFASSUNG 
9 
 
Meropenem und Cefoxitin, als den Hauptfaktor für die angeborene β-Laktam Resistenz in M. 
abscessus. 
Diese Forschungsergebnisse erweitern die Grundlagenkenntnisse über mögliche 
Interventionen für den hoch resistenten Krankheitserreger M. abscessus und deuten auf die 
akute Notwendigkeit der Entwicklung neuer Substanzen hin, die den verschiedenen 
Resistenzmechanismen, vermittelt durch Arr_Mab, AAC(2'), Eis2 sowie Bla_Mab, 
wiederstehen können. 
 
 
  
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
10 
 
 
1. The genus Mycobacterium 
The genus Mycobacterium is the only member of the family Mycobacteriaceae and 
encompasses more than 150 species, including a number of medically important pathogens, 
such as Mycobacterium tuberculosis, that exact an alarming toll in human morbidity and 
mortality. The members of this genus are straight or slightly curved nonmotile rods, 
nonsporeformers, stain Gram-positive, acid-fast, and share an unusually high genomic DNA 
G+C content (62–70%). They have a cell wall rich in long chain fatty acid esters, known as 
mycolic acids, which renders the mycobacteria impervious to many aseptic solutions and 
antibiotics. The Greek prefix “myco” means “fungus”, alluding to the mold-like appearance 
of mycobacterial colonies on the surface of solid media.
1
 
Historically, mycobacteria have been classified into two major groups on the basis of their 
growth rate. Rapid growing mycobacteria (RGM) form colonies on selective media in less 
than 7 days, whereas slow growing mycobacteria (SGM) require greater time periods.
2
 
Generation times range from 2 hours for Mycobacterium smegmatis to 12 days for 
Mycobacterium leprae.
1 
RGM species are usually harmless saprophytes, while SGM are 
frequently associated with mycobacterial diseases.
2
 One remarkable exception to the concept 
of RGM as saprophytes is Mycobacterium abscessus, presently one of the most prevalent and 
the most drug-resistant opportunistic pathogen in human disease among RGM.
3
  
 
2. Nontuberculous Mycobacteria (NTM) 
For diagnostic and treatment purposes mycobacteria are further divided into three major 
groups: (i) M. tuberculosis complex, which comprises M. tuberculosis as well as other 
causative agents of animal and human tuberculosis, such as Mycobacterium bovis and 
Mycobacterium africanum, (ii) Mycobacterium leprae, which causes Hansen’s disease or 
leprosy and (iii) nontuberculous mycobacteria (NTM), which encompass the rest of the 
mycobacterial species that do not cause tuberculosis or leprosy.
4
 NTM are often 
environmental, ubiquitous organisms and are occasionally responsible for opportunistic 
infections throughout the human body with a broad spectrum of virulence.
5
 The most 
common human infections attributed to NTM include pulmonary, skin and soft tissue 
infections and lymphadenitis.
6
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The incidence and prevalence of NTM pulmonary disease have been increasing worldwide 
and lately led to an emerging public health problem.
7
 Despite the geographical distribution of 
NTM, by far, the most common organism associated with lung disease is the Mycobacterium 
avium complex (MAC), followed by M. abscessus complex and Mycobacterium kansasii.
8
   
 
3. Mycobacterium abscessus 
M. abscessus is the most pathogenic, chemotherapy-resistant and arduous to treat 
opportunistic pathogen among NTM and the most common isolated rapidly growing NTM 
associated with pulmonary disease.
9
 Thus, M. abscessus has recently been described as an 
“antibiotic nightmare”.3 
 
3.1 History 
M. abscessus was described for first time by Morris Moore and John Frerichs in 1953. These 
authors reported the isolation of a mycobacterium from a 62-year-old woman who had injured 
her left knee as a child when playing in a farm and had subcutaneous abscess-like lesions 48 
years later. Due to the distinctive morphological, growing and biochemical characteristics of 
this mycobacterium, it was named as a new species, “Mycobacterium abscessus” (type strain 
M. abscessus ATCC 19977
T). The name of this new species “abscessus” was, hence, selected 
because of its ability to produce deep subcutaneous abscesses with a peripherally tuberculoid 
structure.
10 
 
3.2 Taxonomy 
The taxonomic classification of M. abscessus remains presently in debate. After M. abscessus 
first description in 1953 and the recognition of Mycobacterium chelonae in 1972, these two 
RGM organisms were classified as two subspecies of the same species (“M. chelonei” or “M. 
chelonae”).11 Twenty years later, in 1992, M. abscessus was elevated to a species level and 
was separated by M. chelonae.
12
  
After M. abscessus was recognized as an independent species, additional novel species M. 
massiliense and M. bolletii, closely related to M. abscessus (distinct rpoB), were 
INTRODUCTION 
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discovered.
13-14
 Upon observation that M. massiliense and M. bolletii have a completely 
identical 16S rRNA sequence, Leao et al. proposed to combine M. abscessus, M. massiliense 
and M. bolletii in a single species, namely M. abscessus.
15
 Within M. abscessus species, two 
subspecies particularly M. abscessus subsp. abscessus and M. abscessus subsp. bolletii were 
distinguished. The M. abscessus subsp. bolletii was proposed to include those isolates that 
were previously identified as M. massiliense or M. bolletii.
15 
Over the recent years, mounting evidence has emerged that the members of the M. abscessus 
subsp. bolletii designation are not homogenous.
16
 While all of them are opportunistic 
pathogens in humans, they differ in susceptibility to macrolides due to sequence and 
functional diversity of their erm genes. In 2006, and while macrolides were the proposed 
treatment for most susceptible RGM species, Nash et al.
17
 reported that the most clinically 
important RGM from the Mycobacterium fortuitum group (Mycobacterium boenickei, 
Mycobacterium goodii, Mycobacterium houstonense, Mycobacterium mageritense, 
Mycobacterium neworleansense, Mycobacterium porcinum, and Mycobacterium wolinskyi) 
possess an inducible erythromycin ribosomal methylase (erm) gene that confers macrolide 
resistance. Three years later, the same authors communicated the presence of a new erm gene, 
namely erm(41), present in all taxa of M. abscessus.
18 
However, the erm(41) gene of the 
former species M. massiliense has two deletions that render the gene non-functional and 
therefore, clinical isolates of M. massiliense do not show inducible resistance to macrolides, 
the primary therapeutic antibiotics for M. abscessus, and thereby, have more favorable 
treatment outcomes.
19
  
 
Figure 1. Serial nomenclatural and taxonomic changes of Mycobacterium abscessus complex, 1992-2016. 
Adapted from Lee MR, Sheng WH, Hung CC, et al. 2015.
4 
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Recently, more light was shed on the taxonomic position of the members of M. abscessus 
complex by computational sequence analyses. According to prior erm(41)-related phenotypic 
data and genomic data from Tortoli et al., the authors concluded that the 3 members of M. 
abscessus complex do not meet the criteria for differentiation at the species level, but at the 
subspecies level. In that context, the authors suggest that M. abscessus comprises M. 
abscessus subsp. abscessus, M. abscessus subsp. bolletii and a third subspecies for which the 
name M. abscessus subsp. massiliense comb. nov. was proposed. 
20
 
  
3.3 Etiopathogenesis 
M. abscessus is an environmental opportunistic pathogen, found in soil, water and dust. It is 
able to survive in host cells, primarily in macrophages and fibroblasts and therefore is 
considered an intracellular pathogen.
21
 “Smooth” (S) and “rough” (R) morphotypes of M. 
abscessus have been described, which are associated with less severe or more acute human 
infections, respectively.
22
 Most clinically relevant cases are associated with pulmonary 
infections in patients with cystic fibrosis, bronchiectasis or pneumoconiosis and disseminated 
disease in immunocompromised individuals.
9,21-23
 M. abscessus is highly resistant to 
disinfectants, as well, and thereby it often causes skin and soft tissue infections when 
nonsterile techniques are applied or contaminated materials are used during plastic surgery, 
tattooing, body piercing, mesotherapy and acupuncture procedures.
9,24-31 
Several worldwide 
reported healthcare-associated outbreaks of M. abscessus, highlight the increasing medical 
importance of this multidrug-resistant pathogen and the urgent need for reliable medication 
strategies.
9,23,32 
 
Figure 2. Smooth (S) and rough (R) morphotypes of M. abscessus. Figure from Medjahed H, Gaillard JL, Reyrat 
JM. 2010.
33
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3.4 Treatment 
 
Treatment of an M. abscessus infection is long, costly and complicated due to the bacteria’s 
high degree of innate resistance to antimicrobial agents.
34
 Being intrinsically resistant towards 
most classes of antibiotics used for treatment of Gram-positive and Gram-negative bacterial 
infections, like β-lactams, aminoglycosides and macrolides, as well as towards the first-line 
antituberculosis drugs, M. abscessus has been recently characterized an “antibiotic 
nightmare”.3 Indeed, treatment options against M. abscessus infection are more limited than 
for M. tuberculosis infection.
3
 While no standard treatment recommendations for M. 
abscessus infections have yet been established, antibiotic administration is empiric, should be  
individualized and therefore, heavily relies on in vitro antibiotic susceptibility testing (AST) 
by broth microdilution and definitive subspecies identification.
7,9
  
The clinical importance of M. abscessus subspecies identification (M. abscessus subsp. 
abscessus, M. abscessus subsp. bolletii and M. abscessus subsp. massiliense) is attributed to 
the fact that, M. abscessus subsp. abscessus and M. abscessus subsp. bolletii, have a 
functional inducible erythromycin ribosome methyltransferase [erm(41)] gene that confers 
macrolide resistance, whereas M. abscessus subsp. massiliense has a nonfunctional erm(41) 
leading to macrolide susceptibility and thereby, prognosis and treatment outcomes of M. 
abscessus subsp. massiliense infections are more propitious.
17-19,35
  
Apt antibiotics are given for varying periods of time depending on severity and location of M. 
abscessus disease. Skin and soft tissue infections are often successfully treated within 3–6 
months with excellent chance for cure when chemotherapy and concomitant surgical 
debridement are combined. Although there is no standard treatment for pulmonary M. 
abscessus infections, current guidelines from the American Thoracic Society propose periodic 
administration of a multidrug therapy, including an oral macrolide (clarithromycin or 
azithromycin) for clinical isolates susceptible to macrolides and the intravenous 
aminoglycoside amikacin in combination with a parenteral β-lactam antibiotic, cefoxitin or 
imipenem.
36-38
 However, treatment outcomes are extremely poor, often related to adverse 
effects and drug toxicities, while relapse rates are very high.
39
 Lung disease due to M. 
abscessus is, therefore, only considered by clinicians “manageable”, but not “curable”.40 
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3.5 Antibiotic Susceptibility Testing (AST) 
 
M. abscessus is notoriously resistant to standard antituberculosis drugs and most commonly 
administered commercial antibiotics. Therefore, treatment strategies followed by clinicians 
heavily rely on in vitro antibiotic susceptibility testing (AST) results.
3
 The Clinical and 
Laboratory Standards Institute (CLSI), the only organization worldwide that has published 
AST guidelines for RGM, recommends susceptibility testing of amikacin, cefoxitin, 
ciprofloxacin, clarithromycin, doxycycline or minocycline, imipenem, linezolid, 
moxifloxacin, trimethoprim-sulfamethoxazole and tobramycin. The recommended method for 
M. abscessus AST is broth microdilution in cation-adjusted Mueller-Hinton broth.
41 
With the exception of the macrolide class and since clarithromycin became the cornerstone 
for oral M. abscessus treatment, very limited data concerning the correlation between AST 
and the clinical efficacy of the recommended antimycobacterial drugs have been reported in 
the literature.
42
 Among the suggested chemotherapeutic agents for M. abscessus, 
clarithromycin, amikacin and cefoxitin have the best antimycobacterial activity.
9
 However, 
the clinical relevance of AST remains controversial, because of technical problems associated 
with AST methods, reproducibility of AST results, significant discrepancies between in vitro 
susceptibility and in vivo activity of a given drug, solubility and stability issues of the drugs 
used.
43
 For example, M. abscessus inducible macrolide resistance was for long unrecognized 
by Minimal Inhibitory Concentration (MIC) assays, as visual inspection of the MIC  results  
was suggested after 3 days of incubation by CLSI.
44
 Nowadays, it is known that additional 
incubation is needed to detect inducible macrolide resistance and MIC reading should be done 
after 14 days of incubation.
41
  
Nevertheless, despite the problematic correlation of the AST results with the in vivo activity 
of recommended antimycobacterial agents and all the technical issues that logically question 
the clinical utility of AST, the latter still remains the golden standard that guides the 
therapeutic plans chosen by clinicians.
3,43 
 
3.6 Genomics of M. abscessus 
The genome of M. abscessus subsp. abscessus (CIP 104536
T
) consists of a 5,067,172-bp 
circular chromosome, that exhibits 93% of coding capacity (4920 predicted coding sequences) 
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and 64% of G+C content, and a 23-kb mercury resistance plasmid, which is almost identical 
to pMM23 from Mycobacterium marinum.
45
  
The chromosome of M. abscessus subsp. abscessus encodes many virulence proteins and 
numerous enzymes which putatively modify and consequently inactivate antibiotics, thereby 
contributing to complications in treatment of this emerging pathogen.
3,45 
After 2009, when the 
M. abscessus genome sequence became available
45
, several research groups worldwide have 
been motivated to study M. abscessus antibiotic resistance mechanisms. At first, lack of tools 
for the genetic manipulation of M. abscessus severely delayed research endeavours.
3
 
Although progress to this direction has been recently done, (β-lactam and macrolide 
resistance determinants of M. abscessus have been discovered and experimentally 
confirmed)
46-47
, generation of isogenic mutants by targeted gene deletion in M. abscessus is 
still considered challenging. 
 
 
3.7 Genetic Markers 
Implementation of essential and powerful tools for targeted gene deletion in M. abscessus 
would accelerate identification of M. abscessus drug resistance mechanisms. Very recently, 
significant progress has been made towards the development of conditional expression and 
homologous recombination systems for M. abscessus. However, these genetic strategies have 
not overcome the obstacles of low transformation efficiency, which typically leads to a 
limited number of mutants generated, and the high level spontaneous resistance to standard 
antibiotics used for selection, which gives rise to high background levels of false-positive 
colonies.
48-49
 To date, the antibiotic resistance markers that have been applied for the 
generation of deletion mutants in M. abscessus include zeocin-, hygromycin-, kanamycin- 
and,  only recently, apramycin resistance cassettes.
46-47,49-53
 
Apramycin is a broad-spectrum atypical aminoglycoside antibiotic that has been applied in 
animal husbandry, but not in human disease treatment. Production of an aminoglycoside 3-N-
acetyltransferase type IV [AAC(3)IV] confers cross-resistance to apramycin as well as a 
variety of other aminoglycosides. Mycobacterial species, such as M. smegmatis and M. 
fortuitum were known to be highly susceptible to apramycin compared with hygromycin and 
kanamycin.
54
 Likewise, M. tuberculosis and M. abscessus are susceptible towards 
apramycin
55
 and therefore the apramycin resistance gene has the potential to be used, and was 
recently used
53
, as a marker gene for positive selection in M. abscessus.  
INTRODUCTION 
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Isoniazid, also known as isonicotinylhydrazide, is a first-line antituberculosis drug which 
targets InhA (enoyl-acyl carrier protein reductase), an enzyme involved in mycolic acid 
synthesis. As a pro-drug, isoniazid has to be activated by a catalase peroxidase, namely KatG. 
M. abscessus is assumed to be naturally resistant to isoniazid, because its pro-drug activator 
KatG is missing.
56 
Heterologous expression of KatG, therefore, could serve as a negative 
selectable marker that could sensitize M. abscessus to isoniazid.  
Once the barrier of lack of genetic tools for M. abscessus has been overcome, targeted 
deletion of genes putatively involved in drug resistance and virulence mechanisms of M. 
abscessus could be expedited.  
 
3.8 Drug resistance of M. abscessus 
Drug resistance of M. abscessus is conferred by a variety of mechanisms. Intrinsic resistance 
is attributed to low permeability of its complex and rich in lipids cell envelope, which acts as 
a physical and a chemical hydrophobic barrier. Furthermore, production of antibiotic-
modifying/inactivating or drug-target-modifying enzymes and drug export systems contribute 
to intrinsic resistance. In M. abscessus, acquired drug resistance is usually conferred by 
mutations in the target genes, but eventually may also be conferred by horizontal gene 
transfer.
3,45
 Since research attempts into M. abscessus drug resistance mechanisms are 
challenged by the limited number of genetic tools, most of the previous and up to date 
findings on M. abscessus drug resistance constitute hypotheses that were based on discoveries 
in other mycobacterial species, but could not be experimentally addressed in M. abscessus.
3 
 
3.8.1 Macrolide resistance 
One major mechanism that renders M. abscessus resistant to chemotherapeutic agents is the 
modification of the drug target.
3
 This mechanism has been extensively described in the 
context of M. abscessus macrolide resistance. Macrolide antibiotics (mainly azithromycin, 
clarithromycin, erythromycin and roxithromycin) are commonly used for treatment of non-
tuberculous mycobacterial infections, including M. abscessus, M. avium, Mycobacterium 
intracellulare and M. chelonae.
3,9
 Macrolides comprise a group of drugs whose activity stems 
from the presence of a macrolide ring, a large macrocyclic lactone ring to which one or more 
deoxy sugars may be attached. Macrolide antibiotics target the large ribosomal subunit, 
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preventing peptidyltransferase from adding the peptidyl group attached to tRNA to the next 
amino acid and inhibiting ribosomal translocation and thereby, protein synthesis.
57-58
  
Nash et al. reported in 2006 for first time the presence of an inducible erythromycin 
ribosomal methylase (erm) gene, which confers macrolide resistance, in the genome of most 
clinically significant RGM species of the M. fortuitum group.
17
 Bacterial macrolide resistance 
occurs by post-transcriptional methylation of the 23S rRNA at the N-6 position of adenosine 
2058 (A2058) (Escherichia coli numbering), which is a pivotal nucleotide for the binding of 
macrolide antibiotics, thus inhibiting drug attachment.
59
 Three years later (in 2009) and while 
macrolides were the treatment of choice for most susceptible RGM species, the same research 
group described a new erm gene in M. abscessus complex, designated as erm(41).
18
 M. 
abscessus subsp. abscessus and M. abscessus subsp. bolletii have an intact erm gene, which 
exhibits T/C polymorphism at the 28
th
 nucleotide. On the one hand, the erm(41)T28 gene 
product is induced by macrolides and methylates 23S rRNA, thus preventing macrolide 
binding to the ribosome. On the other hand, when cytidine is the 28
th
 nucleotide of the erm 
gene [erm(41)C28], there is a loss of methylation function and thereby, macrolide 
resistance.
60
 About 80% of M. abscessus subsp. abscessus clinical isolates and the vast 
majority of M. abscessus subsp. bolletii isolates have a wild-type erm(41) gene [erm(41)T28] 
and exhibit inducible macrolide resistance, characterized by low or intermediate MICs. The 
erm(41) gene of M. abscessus subsp. massiliense is shorter due to two deletions of nucleotides 
64-65 and 159-432 which result in loss of gene function. As a consequence, such isolates of 
M. abscessus subsp. massiliense do not exhibit inducible macrolide resistance.
19,60-61
 Finally, 
Choi et al. in 2012 experimentally confirmed, by using an M. abscessus subsp. abscessus 
erm(41)-knockout mutant and an M. abscessus subsp. massiliense transformant expressing M. 
abscessus subsp. abscessus wild-type erm(41), that erm(41)T28 is responsible for inducible 
M. abscessus macrolide resistance.
62 
Constitutive macrolide resistance, characterized by high MIC values, was described in all M. 
abscessus complex taxa as a consequence of a mutation at either the A2058 or the A2059 
position of the 23S rRNA gene (rrl).
19,60-61 
Generally, pathogenic species that develop 
macrolide resistance through mutations at A2058 (or neighbouring nucleotides) possess only 
one or two rrn operons. Indeed, Mycobacterium species possess only one rrn operon and 
therefore exhibit resistance to macrolides acquired by mutation in the rrl gene more frequent 
compared to other bacterial species.
63 
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3.8.2 Rifamycin resistance 
Rifampicin, from the group of rifamycin antibiotics, constitutes a semi synthetic product of 
the Streptomyces strain Amycolatopsis rifamycinica.
64
 Although rifampicin is one of the most 
potent and broad spectrum antibiotics against bacterial infections and a key component of 
antituberculosis therapy
65
, it shows only little activity towards M. abscessus. The bacterial 
activity of rifampicin stems from its binding with high affinity to the β subunit of the bacterial 
RNA polymerase thereby inhibiting transcription. Rifampicin binds in a pocket of the RNA 
polymerase β subunit deep in the DNA/RNA channel, but 12,1 Å away from the active site. 
Therefore, the RNA polymerase can bind and catalyze the formation of a phosphodiester bond 
between two substrate nucleotides in the presence of the antibiotic, but the antibiotic sterically 
blocks the path of the elongating RNA when the transcript becomes 2 to 3 nt long.
66-67
  
Mutations within several “hotspots” in rpoB, the gene encoding the β subunit of RNA 
polymerase, is the most frequent mechanism of acquired rifampicin resistance among a 
variety of bacterial species, such as E. coli, M. tuberculosis and Staphylococcus aureus.
67-70
 
However, other resistance mechanisms have been also reported including limited membrane 
permeability to rifampicin and enzymatic inactivation of rifampicin.
71-76
 Especially, M. 
smegmatis is naturally resistant to rifampicin, despite the lack of resistance associated 
polymorphisms in the rpoB target gene.
77
 It is already proved that M. smegmatis produces an 
enzyme called rifampicin ADP-ribosyltransferase that adds an ADP-ribose group to 
rifampicin and thereby, hampers the drug’s ability to bind to RNA polymerase.74 The genome 
of M. abscessus encodes a putative rifampicin ADP-ribosyltransferase that is probably 
involved in M. abscessus high level of rifampicin resistance.
3 
 
3.8.3 Aminoglycoside resistance 
Aminoglycosides are hydrophilic molecules consisting of a characteristic, central 
aminocyclitol linked to one or more amino sugars by pseudoglycosidic bond(s). 
Aminoglycoside antibiotics primary target the bacterial ribosome and specifically, bind to the 
aminoacyl site of 16S ribosomal RNA within the 30S ribosomal subunit, leading to 
misreading of the genetic code and/or inhibition of translocation
78-80
.  
Aminoglycoside resistance typically occurs due to low uptake, energy-dependent bacterial 
efflux, target modification (16S rRNA methylation, mutation of the ribosomal target) or 
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enzymatic drug modification.
80
 M. abscessus genome is supposed to code for numerous 
enzymes that are able to transfer acetyl, adenylyl and phosphate groups on crucial residues of 
aminoglycoside drugs leading to their inactivation. Particularly, M. abscessus encodes a 
putative aminoglycoside 2'-N-acetyltransferase and a number of homologues of additional 
aminoglycoside acetyltransferases and phosphotransferases.
45 
It is hypothesized that these M. 
abscessus enzymes could confer aminoglycoside resistance, but so far no experimental 
evidence could confirm these speculations, which are primarily based on the fact that 
acetyltransferases and phosphotransferases from M. smegmatis and M. tuberculosis have been 
delineated to modify aminoglycoside drugs and endow these species with low level 
aminoglycoside resistance.
81
 However, resistance levels of M. abscessus are much higher, 
eventually suggesting that some enzymes/mechanisms may act synergistically.
82 
 
3.8.4 β-lactam resistance 
In addition to aminoglycoside resistance, M. abscessus also demonstrates high resistance to 
another important group of broad spectrum antibiotics, β-lactams. β-lactam antibiotics contain 
several subgroups of antibiotics, such as penicillins, monobactams, cephalosporins and 
carbapenems. All β-lactams contain a four-member β-lactam ring and selectively restrain the 
synthesis of the peptidoglycan layer of bacterial cell wall.
83-84
 Genuinely, peptidoglycan is a 
polymer consisting of sugars and amino acids that forms a mesh-like layer outside the plasma 
membrane of bacteria, forming their cell wall. The sugar component consists of alternating 
residues of β-(1,4) linked N-acetylglucosamine and N-acetylmuramic acid. Attached to the N-
acetylmuramic acid is a peptide chain of three to five amino acids. The peptide chain is cross-
linked to the peptide chain of another strand forming the 3-dimensional (3-D) mesh-like layer 
which provides the cell wall with strength. This 3-D network is basically established by 
transpeptidases or penicillin binding proteins (PBP).
85
 β-lactams mimic D-alanyl-D-alanine, a 
component of the peptidoglycan, which is imperative for the formation of the crosslinks by 
the PBP. In that way, the transpeptidases are obstructed by β-lactams, no crosslinks are 
accordingly formed, cell wall lacks strength and is, hence, disrupted.
86
  
M. abscessus encodes an Ambler class A β-lactamase (MAB_2875) which hydrolyses the β-
lactam ring. This enzyme is insensitive to β-lactamase inhibitors (such as clavulanate, 
tazobactam and sulbactam) and closely resembles β-lactamases from Gram-negative bacteria 
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(Pseudomonas luteola, Serratia fonticola).
87
 Most likely, MAB_2875 has been acquired by 
horizontal gene transfer.
45
  
 
4. Aims of the study 
M. abscessus possesses various genes, which are hypothesized to be involved in its high 
intrinsic rifamycin, aminoglycoside and β-lactam resistance.34,45 However, the exact function, 
the molecular proof and the interplay of these genes remain under cover. Elucidation of drug 
resistance mechanisms heavily relies on the ability for genetic manipulation of M. abscessus, 
particularly on generation of mutants by targeted gene inactivation. However, research 
endeavours into M. abscessus are hampered by the limited number of available genetic 
tools.
46-53
  
The aims of this Ph.D. Thesis were to: 
 Establish selectable markers for the generation of mutants by targeted gene 
inactivation in M. abscessus.  
 Decipher M. abscessus intrinsic rifamycin resistance mechanisms. 
 Elucidate M. abscessus innate aminoglycoside resistance mechanisms. 
 Characterize M. abscessus β-lactam resistance mechanisms. 
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ABSTRACT 
Objectives: Rifampicin, a potent first-line TB drug of the rifamycin group, shows only little 
activity against the emerging pathogen Mycobacterium abscessus. Reportedly, bacterial 
resistance to rifampicin is associated with polymorphisms in the target gene rpoB or the 
presence of enzymes which modify and thereby inactivate rifampicin. The aim of this study 
was to investigate the role of the MAB_0591 (arrMab)-encoded rifampicin ADP-
ribosyltransferase (Arr_Mab) in innate high-level rifampicin resistance in M. abscessus. 
Methods: Recombinant Escherichia coli and Mycobacterium tuberculosis strains expressing 
MAB_0591 were generated, as was an M. abscessus deletion mutant deficient for MAB_0591. 
MIC assays were used to study susceptibility towards rifampicin and C25 carbamate-modified 
rifamycin derivatives. 
Results: Heterologous expression of MAB_0591 conferred rifampicin resistance to E. coli and 
M. tuberculosis. Rifamycin MIC values were consistently lower for the M. abscessus ΔarrMab 
mutant as compared with the M. abscessus ATCC 19977 parental type strain. The rifamycin 
wild-type phenotype was restored after complementation of the M. abscessus ΔarrMab mutant 
with arrMab. Further MIC data demonstrated that a C25 modification increases rifamycin 
activity in wild type M. abscessus. However, MIC studies in the M. abscessus ΔarrMab mutant 
suggest that C25 modified rifamycins are still subject to modification by Arr_Mab.   
Conclusions: Our findings identify Arr_Mab as the major innate rifamycin resistance 
determinant of M. abscessus. Our data also indicate that Arr_Mab-mediated rifamycin 
resistance in M. abscessus can only in part be overcome by C25 carbamate modification.  
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INTRODUCTION 
Mycobacterium abscessus, an environmental saprophyte, is one of the most pathogenic and 
drug-resistant organisms among rapidly growing mycobacteria (RGM).
1-2
 It accounts for 
~80% of all lung infections due to RGM, particularly exacerbations of chronic lung disease in 
patients with cystic fibrosis or bronchiectasis. M. abscessus is also responsible for skin or soft 
tissue infections, usually following trauma, plastic surgery or esthetic procedures (tattooing 
and body piercing).
3-11
 Currently, there is no reliable antibiotic regimen for the treatment of 
infections with M. abscessus, as this bacterium demonstrates a high level of intrinsic and 
acquired resistance to commonly administered antibiotics.
2-3,7,11
 
Rifampicin is a major chemotherapeutic agent of the rifamycin group.
12-13
 The rifampicin 
mechanism of action is based on its ability to inhibit transcription by binding with high 
affinity to the rpoB-encoded β subunit (RpoB) of the DNA-dependent RNA polymerase of 
prokaryotes.
14-15
 Bacterial rifampicin resistance is mostly attributed to alterations in rpoB, 
responsible for decreased affinity of the RpoB for rifampicin.
15-18
 Less frequent mechanisms 
of rifampicin resistance include limited membrane permeability to rifampicin and enzymatic 
inactivation of rifampicin through modification processes.
19-24
  
Rifampicin resistance mutations have originally been identified and extensively studied in 
Escherichia coli and are mapped in four distinct sequence clusters within the rpoB gene, 
known as the N-terminal cluster (N) and clusters I, II and III.
25-30
 It has subsequently been 
shown that the majority of the rifampicin
 
resistance mutations occur within an 81 bp region of 
cluster I, denoted as the rifampicin resistance-determining region, across all bacterial 
species.
28,31-33
 In Mycobacterium tuberculosis, high-level clinically acquired rifampicin 
resistance is almost always conferred by mutations in rpoB.
34
 In contrast, Mycobacterium 
smegmatis, which is naturally resistant to rifampicin, has rifampicin ADP-ribosyltransferase 
activity conferring innate rifampicin resistance.
22,35-36
 Combrink et al.
37
 delineated that the 
mechanism of Arr_Msm-mediated rifampicin inactivation can be overcome by a series of 3-
morpholino rifamycins in which the C25 acetate group of the rifamycin core was replaced by 
a bulky carbamate group. The C25 carbamate prevents ribosylation of the adjacent C23 
alcohol catalyzed by Arr_Msm and thus C25 rifamycins exhibit improved antimicrobial 
activity compared with rifampicin against M. smegmatis.
37
 
Whole genome sequencing revealed that M. abscessus carries a putative ADP-
ribosyltransferase (Arr_Mab), encoded by MAB_0591 (arrMab).
11,38
 To date, no experimental 
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data have defined the exact function of MAB_0591 nor confirmed its association with M. 
abscessus innate high-level rifampicin resistance.  
We here used heterologous expression of MAB_0591 and targeted deletion of MAB_0591 in 
M. abscessus to identify Arr_Mab as the major relevant rifampicin resistance determinant in 
the type strain M. abscessus ATCC 19977. In addition, our finding that Arr_Mab-mediated 
rifampicin resistance in M. abscessus can hardly be overcome by rifamycin C25 carbamate 
modification has important consequences for the development of new rifamycin derivatives 
active against M. abscessus.  
 
MATERIALS AND METHODS 
RpoB amino acid sequence alignment 
The RpoB sequences of the E. coli K-12, M. tuberculosis H37Rv, M. smegmatis mc
2
155 and 
M. abscessus ATCC 19977 were collected from the National Center for Biotechnology 
Information (NCBI) database (http://www.ncbi.nlm.nih.gov/protein/). Multiple sequence 
alignment was performed using the ClustalW2 program 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
 
Bacterial strains and growing conditions 
(i) E. coli strains were cultivated in LB medium at 37 °C overnight. Ampicillin was added to 
the medium at a final concentration of 120 mg/L, when necessary. For all cloning steps, E. 
coli XL1-Blue MRF’ or E. coli MC1061 were used, whereas E.coli-gfp control strain and 
E.coli-arrMab testing strain were used for Minimal Inhibitory Concentration (MIC) assays. (ii) 
M. abscessus strains were grown in Middlebrook 7H9 liquid medium or on LB agar plates at 
37 °C for 5 days. When needed, apramycin was added at a final concentration of 50 mg/L. 
The M. abscessus ATCC 19977 type strain, M. abscessus ΔarrMab mutant strain, M. abscessus 
ΔarrMab-arrMab complemented mutant strain and M. abscessus ΔarrMab pMV361-aac(3)IV 
vector backbone control strain were used throughout this study. (iii) The M. smegmatis 
mc
2
155 type strain was grown on LB agar plates at 37 °C for 3 days. (iv) M. tuberculosis 
strains were cultivated in Middlebrook 7H9 liquid medium or on Middlebrook 7H10 agar 
plates, at 37 °C for 2-4 weeks and apramycin was added at a final concentration of 50 mg/L, 
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when necessary. The M. tuberculosis H37Rv type strain, Mtb-aac(3)IV control strain and 
Mtb-aac(3)IV-arrMab testing strain were used in this study.  
 
Antibiotics 
Ampicillin, apramycin, amikacin, isoniazid, rifampicin, rifapentine and rifaximin were bought 
from Sigma-Aldrich, Switzerland. The following C25 modified rifamycin derivatives were 
synthesized according to the literature protocol:
37
 (i) 5f: 25-O-Desacetyl-(4-
methoxybenzylaminocarbonyl) 3-morpholino rifamycin S; (ii) 5k: 25-O-Desacetyl-{C-[3-(2-
methoxy-phenyl)-isoxazol-5-yl]-methylaminocarbonyl} 3-morpholino rifamycin S; and (iii) 
5l: 25-O-Desacetyl-[C-(3-pyridin-2-yl-isoxazol-5-yl)-methylaminocarbonyl] 3-morpholino 
rifamycin S. The identity of the compounds was confirmed by Nuclear Magnetic Resonance 
and Mass Spectrometry Analysis. Purity of each compound was >97% as analyzed by HPLC. 
Compounds were dissolved in H2O or DMSO according to the manufacturer’s 
recommendations, were filter sterilized, aliquoted into stock solutions of 5-50 g/L and finally 
stored at -20 °C. 
 
Expression of MAB_0591 in E. coli  
MAB_0591 was amplified from M. abscessus ATCC 19977 genomic DNA by Phusion High-
Fidelity DNA Polymerase PCR (5ʹ-ATA TAT GCT CTT CTA GTA CGA TGC CCA ACT 
TTT TGA-3ʹ and 5ʹ-TAT ATA GCT CTT CAT GCG TCA TAG ATG ACC GCG TTT CC-
3ʹ). Following initial cloning into the pINIT vector, the sequence-verified MAB_0591 
amplicon was inserted downstream of the arabinose inducible pBAD promoter into the multi-
copy expression vector pBXNH3 via a fragment exchange (FX) cloning system.
39
 The 
resulting E. coli MC1061 pBXNH3-arrMab testing strain is referred to as E.coli-arrMab. As a 
control, gfp (green fluorescence protein) was amplified from pOLYG-gfp-hyg vector (5ʹ-ATA 
TAT GCT CTT CTA GTA TCT CGA AGG GCG AGG AGC T-3ʹ and 5ʹ-TAT ATA GCT 
CTT CAT GCC TTG TAC AGC TCG TCC ATG CCG-3ʹ) and was cloned directly into 
pBXNH3 expression vector. The resulting E. coli MC1061 pBXNH3-gfp control strain 
expressing gfp is referred to as E.coli-gfp. Gene expression of MAB_0591 and gfp was 
conducted by induction of 30 mL bacterial cultures (OD600 = 0.85-1) with L-arabinose at a 
final concentration of 0.2% v/v, at 37 °C for 4.5 h.  
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Expression of MAB_0591 in M. tuberculosis 
MAB_0591 (including its native promoter) was PCR amplified from M. abscessus ATCC 
19977 genomic DNA using KpnI-linker modified primers 5ʹ-AG GGTACC CGG ATA TGT 
GCA GCG GCA TG-3ʹ and 5ʹ-GA GGTACC CAC CGA AGC ACT GAA GGT GC-3ʹ and 
cloned into the KpnI site of the pMV361-aac(3)IV vector to result in the pMV361-aac(3)IV-
MAB_0591 complementing vector. The control backbone vector [pMV361-aac(3)IV] and the 
complementing vector [pMV361-aac(3)IV-MAB_0591] were transformed in electrocompetent 
M. tuberculosis H37Rv type strain, as previously described for Mycobacterium bovis BCG.
40
 
In brief, 400 μL of M. tuberculosis H37Rv competent cells were mixed with 1 μg of 
supercoiled plasmid DNA and electroporated in a BioRad Gene pulser II (settings: 2.5 kV, 
1000 Ohms and 25 μF). Following electroporation, cells were resuspended in 4 mL of 7H9-
OADC-Tween and incubated for 20 h at 37 °C. Appropriate dilutions were plated on selective 
agar and after 3 weeks of incubation, single colonies were picked, restreaked and grown in 
liquid broth when necessary. The Mtb-aac(3)IV control strain and the Mtb-aac(3)IV-arrMab 
testing strain were obtained by positive selection on 7H10 plates containing apramycin. The 
presence of the aac(3)IV and/or the MAB_0591 gene(s) in these strains was confirmed by 
colony PCR.  
 
Deletion of MAB_0591 in M. abscessus  
An 1.3-kbp PscI/NotI fragment from position 591427 to 592720 (5ʹ arrMab flanking sequence) 
and an 1.3-kbp NotI/XbaI fragment from position 593015 to 594322 (3ʹ arrMab flanking 
sequence) were PCR amplified using genomic DNA from M. abscessus ATCC 19977 (5ʹ-
GAAATT ACATGT GTC ACG ATC TCC TGG ACT GCC TC-3ʹ, 5ʹ-GAAA GCGGCCGC 
CAT GGA AGT ACG CAC CCG ATT CG-3ʹ and 5ʹ-GATA GCGGCCGC CCG AAT TCA 
TGG AAA CCT TCC GGG-3ʹ, 5ʹ-G TCTAGA GTC CTG TGT GAA CAG GTC GGT G-3ʹ, 
respectively) and stepwise cloned into the pSE-katG-aac(3)IV suicide vector resulting in the 
knock-out vector pSE-katG-aac(3)IV-ΔMAB_0591. Details on the construction of M. 
abscessus deletion mutant will be described elsewhere (A. Rominski, P. Selchow and P. 
Sander, unpublished results). Briefly, pSE-katG-aac(3)IV-ΔMAB_0591 was transformed into 
electrocompetent M. abscessus ATCC 19977. For electroporation, 100 μL competent cells 
were mixed with 1-2 μg supercoiled plasmid DNA and electroporated in a BioRad Gene 
pulser II with the following settings: 2.5 kV, 1000 Ohms and 25 μF. After electroporation 
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cells were resuspended in 0.9 mL of 7H9 medium and incubated for 5 h with constant shaking 
(1000 rpm) at 37 °C. Appropriate dilutions were subsequently plated on selective agar and 
after 5 days of incubation, single colonies were picked, restreaked and grown in liquid broth 
when necessary. Transformants were selected on LB agar plates containing apramycin and 
identified by aac(3)IV PCR. Single crossover transformants were identified by Southern blot 
analysis with a 0.2-kbp EcoRI 5ʹ arrMab DNA probe (the same probe was also used for all 
subsequent Southern blot analyses) and subjected to counterselection on LB agar plates 
containing isoniazid (32 mg/L). Single colonies were screened for deletion of MAB_0591 by 
PCR and the genotype was finally confirmed by Southern blot analysis. In this way, a 0.3-kbp 
region of the MAB_0591 was deleted. For complementation of the M. abscessus ΔarrMab 
mutant with MAB_0591, the previously described complementation vector pMV361-
aac(3)IV-MAB_0591 was transformed into the ΔarrMab mutant strain. Transformation was 
verified by Southern blot analysis. 
 
Susceptibility testing of M. tuberculosis strains  
Drug susceptibility testing (DST) was performed using the MGIT 960 system as 
recommended by the manufacturer
41
 and results were interpreted as described previously by 
Springer et al.
42 
 In brief, 0.5 mL dilutions of positive MGIT vials of the Mtb-aac(3)IV control 
strain and the Mtb-aac(3)IV-arrMab testing strain were inoculated in fresh vials containing 
constant levels of apramycin for plasmid maintenance and different concentrations of the test 
drugs.
43
 Rifampicin was tested at concentrations of 1, 4 and 20 mg/L, while the control drug 
isoniazid was tested at concentrations of 0.1, 1, 3 and 20 mg/L, respectively. For the drug free 
growth control, the bacterial working suspension was diluted 1:100 with sterile NaCl and 0.5 
mL of the diluted working suspension was inoculated into the tube (proportion testing).
44
 All 
MGIT tubes were incubated in the MGIT 960 instrument and monitored using the EpiCenter 
(version 5.53) software equipped with the TB eXiST module (Becton Dickinson, 
Switzerland).  
 
Rifampicin Etest 
Bacterial suspensions of M. abscessus ATCC 19977, M. abscessus ΔarrMab and M. abscessus 
ΔarrMab-arrMab strains were adjusted to a McFarland standard of 0.50 and were subsequently 
spread on LB agar plates using a sterile cotton swab. Then, a rifampicin Etest strip 
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(Biomérieux, Switzerland) was placed on each plate and plates were incubated for 5 days at 
37 °C. The point of intersection between bacterial growth and the Etest device was read as 
MIC value.  
 
MIC assays 
MIC assays were performed according to the CLSI guidelines.
45 
Working solutions were 
prepared by diluting the antibiotic stock solutions in Cation-Adjusted Müller-Hinton Broth 
(CAMHB; pH 7.4) (Becton Dickinson, Switzerland) to a concentration corresponding to twice 
the desired final concentration [working solutions of 128, 512 and 1024 mg/L were prepared, 
when the highest concentrations tested at the MIC assay were 64, 256 and 512 mg/L, 
respectively (Table 1, Table 3)]. By using CAMHB in sterile 96-well microtiter plates 
(Greiner Bio-One, Switzerland), two-fold serial dilutions of the working solutions were 
prepared. A positive growth control lacking antibiotic and a sterile negative control containing 
only CAMHB were included in each 96-well microtiter plate. For the preparation of the 
inoculum, 3-4 colonies from each bacterial strain grown on LB agar were transferred into a 
glass tube containing 2 mL of NaCl using a sterile cotton swab. In order to achieve a final 
inoculum titer of 1-5 x 10
5
 cfu/mL, all bacterial suspensions were adjusted to a McFarland 
standard of 0.50 and subsequently diluted in CAMHB. The final test volume in each well of 
the microtiter plate was 0.1 mL. The correct titer of each inoculum was checked by obtaining 
cfu counts on LB agar plates. All microdilution plates were capped with adhesive sealing 
covers and incubated at 37 °C for i) 16 h for E. coli strains and ii) 3, 5, 7 and 12 days for M. 
abscessus and M. smegmatis strains, before the MIC values were assessed by visual 
inspection. All MIC assays were conducted in triplicate. 
 
RESULTS AND DISCUSSION 
Analysis of the RpoB rifampicin
 
resistance sequence clusters from M. abscessus 
To investigate whether innate rifampicin resistance in M. abscessus (MIC: 128 mg/L) is 
associated with polymorphisms in the RNA polymerase β-subunit, we aligned the RpoB 
amino acid sequence of M. abscessus ATCC 19977 with those of E. coli K-12 and M. 
tuberculosis H37Rv, known to be naturally susceptible to rifampicin,
13,16
 and M. smegmatis 
mc
2
155 that has no polymorphism in its rpoB gene corresponding to any known rifampicin 
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resistance genotype,
35
 but is naturally resistant to rifampicin through ADP-ribosylation of 
rifampicin.
22,36
 Our analysis revealed no polymorphism known to confer rifampicin resistance 
within all four (N, I, II and III) rifampicin resistance sequence clusters of M. abscessus RpoB 
(Figure 1), suggesting that other mechanisms are involved in the high intrinsic rifampicin 
resistance of M. abscessus. Possible mechanisms include efflux of rifampicin, diminished 
uptake of rifampicin, and enzymatic degradation or modification of rifampicin.
19-23
 The latter 
resistance mechanism has been studied in M. smegmatis and in Legionella pneumophila.
22-23
 
A recent genome analysis suggested that M. abscessus carries a putative rifampicin ADP-
ribosyltransferase (Arr_Mab),
38
 encoded by MAB_0591 (arrMab). MAB_0591 has 66% amino 
acid sequence identity with the M. smegmatis ADP-ribosyltransferase that modifies 
rifampicin. However, Table S1, which lists the MIC values of selected mycobacterial standard 
strains
42,46-47 
as well as information about the presence or absence of ADP-ribosyltransferase-
like protein in these species, shows that a direct correlation between rifampicin MIC and the 
presence or absence of ADP-ribosyltransferase-like proteins does not exist. M. tuberculosis 
and M. leprae were predicted to have no ADP-ribosyltransferase-like proteins and are 
susceptible to rifampicin (MIC: <1 mg/L).
42,47
 ADP-ribosyltransferases were predicted to be 
present in M. abscessus (M. abscessus subsp. abscessus and M. abscessus subsp. bolletii) and 
M. fortuitum and these species are resistant (MIC: ≥64 mg/L).46 In contrast, the presence of 
putative ADP-ribosyltransferases in e.g. Mycobacterium phlei, Mycobacterium gilvum and 
Mycobacterium marinum does not correlate with high rifampicin MIC levels (MIC: <0.5 
mg/L).
46
 Therefore a functional role of ADP-ribosyltransferases in rifampicin resistance has 
to be addressed experimentally. By using ADP-ribosyltransferase of M. smegmatis mc
2
155 in 
a BLASTP search, we identified also other, non-mycobacterial species predicted to possess 
ADP-ribosyltransferase-like proteins (Table S2). Interestingly, mycobacterial ADP-
ribosyltransferases show homology to the catalytic domain of Exotoxin A from Pseudomonas 
aeruginosa,
48-49
 pointing to a putative role of mycobacterial ADP-ribosyltransferases as 
virulence factors. However, within this study we exclusively focus on the role of MAB_0591 
in rifamycin resistance. 
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Figure 1. Rifampicin resistance regions of RpoB and their association with the interactions between rifampicin 
and the prokaryotic RNA polymerase (RNAP). (a) The bar on top illustrates the RNAP β subunit from E. coli. 
Directly above its amino acid numbering is indicated. Dark red lines within the bar indicate the position of the 
four clusters [N-terminal (N), and clusters I, II and III (I, II and III)] where the rifampicin
 
resistance conferring 
alterations are identified across all bacterial species.
24-30
 Directly below follows the amino acid sequence 
alignment spanning the rifampicin resistance regions of the E. coli K-12, M. tuberculosis H37Rv, M. smegmatis 
mc
2
155 and M. abscessus ATCC 19977 RpoB. Amino acid substitutions that confer rifampicin
 
resistance are 
shown as coloured triangles above and below the alignment, respectively. The possible substitutions for each 
position are mentioned in single amino acid code in columns directly above (for E. coli) or below the coloured 
triangles (for M. tuberculosis). The yellow triangles represent the residues that interact directly with rifampicin 
binding. In contrast, the red triangles indicate residues that are positioned too far away to have direct interaction 
with rifampicin. The blue triangles show the positions that are substituted with the highest frequency among M. 
tuberculosis rifampicin-resistant isolates.
31
 The green triangles show a residue that is directly interacting with 
rifampicin, but no substitutions have been reported at this position, probably because they would be fatal for the 
bacterium.
15
 (b) Using the same colour code for the amino acid positions as above (a), the residues of direct 
interaction with rifampicin (Rif) are shown (yellow, blue and green triangles).  Hydrogen bonds formed between 
an RpoB residue and rifampicin are depicted as dashed lines and residues that form van der Waals interactions 
are indicated in zigzag circles. Numbering of the residues is according to the E. coli positions.
15 
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Heterologous expression of MAB_0591 in E. coli and M. tuberculosis  
To study if rifampicin resistance in M. abscessus is due to arrMab, we cloned MAB_0591 and 
expressed the recombinant protein in two rifampicin susceptible hosts, E. coli
16
 and M. 
tuberculosis.
50
 First, we addressed the question whether induced expression of MAB_0591 
would confer rifampicin resistance in a non-mycobacterial heterologous host. Arr_Mab was 
recombinantly expressed by the multi-copy pBXNH3-arrMab vector in E. coli MC1061 under 
the control of the L-arabinose inducible pBAD promoter. The E.coli-gfp control strain and the 
E.coli-arrMab testing strain were generated following transformation with the pBXNH3-gfp 
and the pBXNH3-arrMab vectors, respectively. The recombinant strains were subsequently 
tested against rifampicin in MIC assays. The E.coli-arrMab testing strain was highly resistant 
to rifampicin with MIC values >512 mg/L, while the E.coli-gfp control strain remained 
susceptible to rifampicin (MIC: 4 mg/L) (Table 1). These results confirm that Arr_Mab plays 
a critical role as a rifampicin resistance determinant when expressed in the rifampicin 
susceptible E. coli host. We hypothesize that Arr_Mab modifies rifampicin by ADP-
ribosylation at the hydroxyl group of C23, as previously shown for Arr_Msm
48
 and that this 
modification interferes with target binding. 
 
Table 1. DST results of E. coli expressing MAB_0591
*
  
 
 
 
 
Next, we studied whether arrMab confers rifampicin resistance in a mycobacterial host, M. 
tuberculosis. In order to simulate veritable levels of Arr_Mab expression, we expressed 
MAB_0591 under control of its native promoter. The single-copy integrating plasmids 
pMV361-aac(3)IV and pMV361-aac(3)IV-MAB_0591 were engineered and transformed into 
the rifampicin susceptible M. tuberculosis H37Rv strain (MIC: <1 mg/L).
42
 The aac(3)IV 
gene that confers resistance towards apramycin was used as positive selection marker. The 
resulting strains referred to as Mtb-aac(3)IV control strain and Mtb-aac(3)IV-arrMab testing 
strain respectively, were subjected to DST using the MGIT 960 system equipped with the 
EpiCenter TB eXiST software. Susceptibility to different concentrations of rifampicin (1, 4 
Strains Rifampicin MIC (mg/L) 
E.coli-gfp 4 
E.coli-arrMab >512 
*
Broth microdilution method 
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and 20 mg/L) and the non-substrate control drug isoniazid (0.1, 1, 3 and 10 mg/L) was 
determined. The Mtb-aac(3)IV control strain was, as expected, susceptible to both rifampicin 
and isoniazid at all concentrations tested (MIC: rifampicin <1.0 mg/L; isoniazid <0.1 mg/L). 
In contrast, the Mtb-aac(3)IV-arrMab testing strain was specifically resistant to rifampicin, 
even at the highest concentration tested (MIC: >20 mg/L), but remained susceptible to the 
unrelated control drug isoniazid (MIC: <0.1 mg/L) (Table 2). These findings demonstrate that 
MAB_0591 confers high-level resistance to rifampicin, but not to other drugs, when expressed 
in a rifampicin-susceptible mycobacterial host.  
 
Table 2. DST results of M. tuberculosis expressing MAB_0591
** 
 
 Rifampicin Isoniazid 
Strains 1.0 mg/L 4.0 mg/L 20.0 mg/L 0.1 mg/L 
Mtb-aac(3)IV S S S S 
Mtb-aac(3)IV-arrMab R R R S 
**
Proportion method using the MGIT 960 system 
S=susceptible; R=resistant 
 
 
Generation of M. abscessus MAB_0591 deletion mutant  
Heterologous expression of MAB_0591 indicated that arrMab is able to confer rifampicin 
resistance to a susceptible host; however its role in innate rifampicin resistance in M. 
abscessus remained to be determined. We recently developed tools for genetic manipulation 
of M. abscessus (A. Rominski, P. Selchow and P. Sander, unpublished results) and wished to 
exploit this technique to generate an M. abscessus MAB_0591 deletion mutant. This mutant 
would allow us to directly address the role of MAB_0591 in innate rifampicin resistance. The 
arrMab deletion mutant was constructed by transformation of M. abscessus ATCC 19977 with 
suicide plasmid pSE-katG-aac(3)IV-ΔMAB_0591 applying apramycin positive selection51 and 
a katG-dependent isoniazid counterselection strategy that we previously established (A. 
Rominski, P. Selchow and P. Sander, unpublished results) (Figure 2a).
 
Deletion of MAB_0591 
was confirmed by Southern blot analysis (Figure 2b). A complemented mutant strain was 
constructed by transformation of M. abscessus ΔarrMab mutant with the complementation 
vector pMV361-aac(3)IV-MAB_0591 expressing Arr_Mab. The complemented mutant strain 
CHAPTER 1 
 
41 
 
is referred to as M. abscessus ΔarrMab-arrMab. Genetic complementation was confirmed by 
Southern blot analysis (Figure 2b). 
 
Figure 2. Genotypic analyses of M. abscessus arrMab locus. (a) Schematic drawing of genotypes and 
recombination events. (b) Southern blot analysis confirms the deletion of MAB_0591 from the genome of M. 
abscessus. Genomic DNA of M. abscessus ATCC 19977 (1), M. abscessus transformant with arrMab targeting 
vector [pSE-katG-aac(3)IV-ΔMAB_0591] prior to (2) and after KatG-dependent isoniazid-counterselection (3) 
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and after transformation of counterselected mutant with arrMab complementation vector (4) was digested with 
EcoRI and probed with a fragment from the 5ʹ arrMab flanking region. M = Molecular Marker. Based on M. 
abscessus genome annotation and vector sequence, the pattern is consistent with hybridization to a 2.65-kbp 
fragment of the wild-type (wt) parental strain, to the 2.36-kbp and 7.45-kbp fragments after site-specific 
homologous recombination [single crossover (sco)], to a 2.36-kbp fragment of the ΔarrMab mutant (Δ) and to the 
2.36-kbp and 3.65-kbp fragments of the M. abscessus ΔarrMab-arrMab complemented mutant strain (C). 
 
Figure 3. Contribution of MAB_0591 to rifampicin resistance in M. abscessus. Rifampicin susceptibility of (a) 
M. abscessus ATCC 19977 wild-type strain, (b) M. abscessus ΔarrMab mutant and (c) M. abscessus ΔarrMab-
arrMab complemented mutant strain, was examined by Etest. The picture of the rifampicin Etest results was taken 
after 5 days of incubation at 37 °C. 
 
DST of M. abscessus ΔMAB_0591  
For determination of the ΔarrMab mutant’s phenotype, a rifampicin Etest was carried out with 
M. abscessus ATCC 19977, M. abscessus ΔarrMab mutant and M. abscessus ΔarrMab-arrMab 
complemented strain. Etest results after 5 days of incubation at 37 °C revealed high-level 
rifampicin resistance in M. abscessus ATCC 19977 (MIC: >32mg/L). In contrast, the ΔarrMab 
mutant showed susceptibility to low rifampicin concentrations (MIC: ≈0.5 mg/L). Rifampicin 
resistance was restored upon complementation of the ΔarrMab mutant strain with arrMab 
[(MIC: >32 mg/L); Figure 3]. MIC values were subsequently determined in detail for 
rifampicin, rifapentine and rifaximin. M. abscessus ATCC 19977, M. abscessus ΔarrMab, M. 
abscessus ΔarrMab-arrMab complemented mutant, M. abscessus ΔarrMab pMV361-aac(3)IV 
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vector backbone control strain and M. smegmatis mc
2
155 were subjected to DST. For M. 
abscessus ΔarrMab the MICs of all rifamycins were consistently and significantly lower than 
for M. abscessus ATCC 19977 wild-type strain, indicating that all tested rifamycins are 
modified by Arr_Mab (Table 3). Transformation of M. abscessus ΔarrMab mutant with arrMab, 
restored wild-type levels of rifamycin resistance while transformation with the empty vector 
backbone did not. Expectedly, amikacin MICs were independent of the arr genotype. These 
findings identify Arr_Mab as the major rifamycin resistance determinant in M. abscessus.  
 
DST of C25 modified rifamycin derivatives 
Carbamate modification at the C25 position of the rifamycin core has been shown to improve 
antimicrobial activity against M. smegmatis mc
2
155.
37
 We wanted to test whether these 
compounds also overcome rifamycin resistance in M. abscessus. C25 modified rifamycin 
derivatives 5f, 5k and 5l (Figure 4) were custom synthesized and tested for antimicrobial 
activity. The compounds showed potent activity against M. smegmatis – on average these 
compounds were 100 – 200-fold more active than rifampicin. These results confirm former 
findings that C25 modified rifamycins apparently are resilient to modification by Arr_Msm. 
The C25 modified rifamycins also showed increased activity in M. abscessus as compared to 
rifampicin, rifapentine and rifaximin (Table 3). Of note, C25 modification not only increases 
rifamycin activity against the M. abscessus wild type, but also against the M. abscessus 
ΔarrMab mutant, although to a lesser extent. These data indicate that the increased activity of 
C25 rifamycin derivatives is only partially due to resilience towards Arr_Mab-modification. 
Compared to compounds 5f and 5k, we observed little time-dependent increase of the MIC 
values for compound 5l in wild type M. abscessus and M. abscessus ΔarrMab-arrMab 
complemented mutant, indicating that 5l is probably least modified by Arr_Mab, but still 
wild-type MIC values are high (4 mg/L; 16-fold higher than against the ΔarrMab mutant).  
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Figure 4. Rifampicin (RIF) and the 5f: 25-O-Desacetyl-(4-methoxybenzylaminocarbonyl) 3-morpholino 
rifamycin S, 5k: 25-O-Desacetyl-{C-[3-(2-methoxy-phenyl)-isoxazol-5-yl]-methylaminocarbonyl} 3-
morpholino rifamycin S and 5l: 25-O-Desacetyl-[C-(3-pyridin-2-yl-isoxazol-5-yl)-methylaminocarbonyl] 3-
morpholino rifamycin S, C25 carbamate rifamycin derivatives, which are numbered per the original work,
37
 for 
ease of comparison. 
 
Conclusions 
Taken together, our study identified Arr_Mab as the major determinant of innate rifamycin 
resistance in M. abscessus. Our data indicate significant species-specific differences in 
rifamycin-C25-mediated resilience for Arr_Msm and Arr_Mab, since Arr_Mab-mediated 
rifamycin resistance can only partly be overcome by C25 modification. These findings testify 
to the need to develop novel compounds that are able to escape Arr_Mab-mediated rifamycin 
resistance in M. abscessus.  Structural similarity between Arr_Msm and protein ADP-
ribosyltransferases, prominently domain III of Pseudomonas aeruginosa exotoxin A have 
been described.
48-49
 These structural features are also conserved in Arr_Mab. Therefore, it is 
tempting to speculate on a dual role of Arr_Mab in drug resistance and virulence. 
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SUPPLEMENTARY DATA 
 
Table S1. Distribution of ADP-ribosyltransferase-like proteins in selected mycobacterial 
species and rifampicin MIC 
  
Species (Standard Strain) RGM/SGM ADP-ribosyltransferase MIC rifampicin 
(mg/L)
42,46-47 
M. smegmatis mc
2
155 RGM + 128 
M. abscessus subsp. abscessus (ATCC 19977) RGM + >256 
M. abscessus subsp. bolletii (CIP 108541) RGM + >256 
M. tuberculosis H37Rv  SGM - <1 
M. leprae Thai-53 SGM - <1 
M. chelonae (NCTC 946) RGM + 64 
M. fortuitum (ATCC 6841) RGM + 64 
M. peregrinum (ATCC 14467)  RGM + 2 
M. doricum (ATCCBAA 565) RGM - 64 
M. obuense (ATCC 27023) RGM + 16 
M. phlei (ATCC 11758) RGM + <0.5 
M. duvalii (ATCC 43910) RGM - <0.5 
M. parafortuitum (ATCC 19686) RGM - 4 
M. gilvum (ATCC 43909) RGM + <0.5 
M. flavescens (ATCC 14474) RGM - 16 
M. intracellulare (ATCC 13950) SGM - 2 
M. xenopi (NCTC 10042) SGM + 1 
M. senegalense (ATCC 35796) SGM - 2 
M. gordonae (ATCC 14470) SGM - <0.5 
M. marinum (ATCC 927) SGM + <0.5 
M. kansasii (ATCC 12478) SGM - <0.5 
M. scrofulaceum (ATCC 19981) SGM + 0.5 
M. malmoense (ATCC 29571) SGM - 1 
M. avium (ATCC 25291) SGM - 8 
M. szulgai (NCTC 10831) SGM + <0.5 
M. terrae (ATCC 15755) SGM - 1 
M. simiae (ATCC 25275) SGM + 8 
RGM= rapidly growing mycobacteria; SGM= slow growing mycobacteria 
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Table S2. Distribution of ADP-ribosyltransferase-like proteins in non-mycobacterial species 
 
 
Description Query 
coverage 
E-value Identity Accession 
NAD(+)-rifampin ADP-ribosyltransferase 
[Rhodococcus opacus] 
100% 1.00E-77 79% WP_043826678.1 
NAD(+)-rifampin ADP-ribosyltransferase 
[Gordonia bronchialis] 
98% 5.00E-76 79% WP_012832191.1 
rifampin ADP-ribosyl transferase 
[Cryobacterium arcticum] 
100% 1.00E-73 76% WP_066598497.1 
rifampin ADP-ribosyl transferase 
[Gordonia polyisoprenivorans] 
100% 1.00E-70 73% WP_006368867.1 
rifampin ADP-ribosyl transferase 
[Cellulomonas fimi] 
100% 1.00E-68 70% WP_013771728.1 
rifampin ADP-ribosyl transferase 
[Cryobacterium roopkundense] 
100% 6.00E-68 70% WP_035838358.1 
rifampin ADP-ribosyl transferase 
[Ornithinimicrobium pekingense] 
97% 5.00E-67 70% WP_022921799.1 
rifampin ADP-ribosyl transferase 
[Microlunatus phosphovorus] 
97% 6.00E-67 70% WP_041790446.1 
rifampin ADP-ribosyl transferase 
[Williamsia herbipolensis] 
100% 4.00E-66 70% WP_045824634.1 
rifampin ADP-ribosyl transferase 
[Streptomyces flavochromogenes] 
100% 4.00E-66 66% WP_030319906.1 
rifampin ADP-ribosyl transferase 
[Serinicoccus profundi] 
97% 1.00E-65 70% WP_010146955.1 
rifampin ADP-ribosyl transferase 
[Streptomyces durhamensis] 
100% 1.00E-64 67% WP_031173901.1 
rifampin ADP-ribosyl transferase 
[Propionicicella superfundia] 
97% 5.00E-63 70% WP_028709133.1 
rifampin ADP-ribosyl transferase 
[Lysinimicrobium gelatinilyticum] 
99% 4.00E-62 68% WP_062516799.1 
rifampin ADP-ribosyl transferase 
[Nocardiopsis kunsanensis] 
100% 7.00E-62 67% WP_017576663.1 
rifampin ADP-ribosyl transferase 
[Arthrobacter alpinus] 
97% 3.00E-61 68% WP_062289126.1 
rifampin ADP-ribosyl transferase 
[Cellulomonas flavigena] 
100% 5.00E-61 65% WP_013115596.1 
rifampin ADP-ribosyl transferase 
[Rhodococcus fascians] 
100% 6.00E-61 64% WP_032395579.1 
rifampin ADP-ribosyl transferase 
[Demequina globuliformis] 
100% 1.00E-60 67% WP_062076570.1 
rifampin ADP-ribosyl transferase 
[Gordonia terrae] 
100% 4.00E-60 62% WP_033206549.1 
rifampin ADP-ribosyl transferase 
[Williamsia muralis] 
100% 8.00E-60 62% WP_062794673.1 
rifampin ADP-ribosyl transferase 
[Aeromicrobium marinum] 
100% 1.00E-59 64% WP_007077209.1 
rifampin ADP-ribosyl transferase 
[Lysinimicrobium rhizosphaerae] 
100% 2.00E-59 66% WP_062526649.1 
rifampin ADP-ribosyl transferase 
[Lysinimicrobium subtropicum] 
97% 6.00E-59 68% WP_062301052.1 
rifampin ADP-ribosyl transferase 100% 7.00E-59 66% WP_062318234.1 
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[Lysinimicrobium aestuarii] 
rifampin ADP-ribosyl transferase 
[Streptomyces lavenduligriseus] 
100% 6.00E-58 68% WP_030788496.1 
rifampin ADP-ribosyl transferase 
[Actinotalea ferrariae] 
100% 1.00E-57 63% WP_034227635.1 
rifampin ADP-ribosyl transferase 
[Gordonia namibiensis] 
100% 2.00E-57 60% WP_040535037.1 
rifampin ADP-ribosyl transferase 
[Streptomyces globisporus] 
100% 2.00E-56 65% WP_030691134.1 
rifampin ADP-ribosyl transferase 
[Gordonia amicalis] 
100% 3.00E-56 60% WP_024497540.1 
rifampin ADP-ribosyl transferase 
[Gordonia kroppenstedtii] 
97% 5.00E-56 70% WP_026303538.1 
rifampin ADP-ribosyl transferase 
[Streptomyces venezuelae] 
100% 3.00E-55 65% WP_055639481.1 
rifampin ADP-ribosyl transferase 
[Nocardia farcinica] 
93% 4.00E-55 61% WP_068971096.1 
rifampin ADP-ribosyl transferase 
[Gordonia paraffinivorans] 
96% 7.00E-55 63% WP_006900611.1 
hypothetical protein  
[Cellulomonas massiliensis] 
95% 1.00E-54 63% WP_019136146.1 
rifampin ADP-ribosyl transferase 
[Flavihumibacter petaseus] 
88% 4.00E-53 63% WP_046368559.1 
rifampin ADP-ribosylating transferase 
ARR-2 [Modestobacter marinus] 
92% 7.00E-53 63% WP_051144103.1 
rifampin ADP-ribosylating transferase 
[Modestobacter marinus] 
92% 1.00E-52 63% CCH85944.1 
rifampin ADP-ribosyl transferase 
[Clostridium propionicum] 
92% 4.00E-52 63% WP_066053732.1 
rifampin ADP-ribosylating transferase 
[Saccharomonospora paurometabolica] 
88% 2.00E-51 63% WP_007026413.1 
rifampin ADP-ribosyl transferase 
[Pontibacter actiniarum] 
98% 2.00E-51 56% WP_025607027.1 
rifampin ADP-ribosylating transferase 
[Sphingobacterium spiritivorum] 
89% 2.00E-51 60% WP_003006667.1 
rifampin ADP-ribosyl transferase 
[Desulfitobacterium hafniense] 
96% 5.00E-51 58% WP_005811445.1 
rifampin ADP-ribosyl transferase 
[Variovorax paradoxus] 
95% 5.00E-51 60% WP_057592616.1 
rifampin ADP-ribosyl transferase 
[Caulobacter vibrioides] 
89% 7.00E-51 62% WP_058349090.1 
rifampin ADP-ribosylating transferase 
[Cytophaga hutchinsonii] 
98% 9.00E-51 56% WP_011585690.1 
rifampin ADP-ribosyl transferase 
[Streptomyces purpeofuscus] 
100% 3.00E-50 57% WP_063764233.1 
rifampin ADP-ribosyl transferase [Knoellia 
aerolata] 
93% 3.00E-50 61% WP_052112740.1 
rifampin ADP-ribosyl transferase 
[Pontibacter roseus] 
91% 3.00E-50 59% WP_018478319.1 
rifampin ADP-ribosyl transferase 
[Streptomyces kanamyceticus] 
90% 4.00E-50 62% WP_055545547.1 
rifampin ADP-ribosylating transferase 
[Oscillatoria nigro-viridis] 
91% 4.00E-50 60% WP_015175623.1 
rifampin ADP-ribosylating transferase 92% 5.00E-50 59% WP_009965045.1 
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[Verrucomicrobium spinosum] 
rifampin ADP-ribosylating transferase 
[Clostridium bolteae] 
92% 5.00E-50 56% WP_002571935.1 
rifampin ADP-ribosyl transferase 
[Clostridium neopropionicum] 
92% 5.00E-50 60% WP_066091112.1 
rifampin ADP-ribosyl transferase 
[Pseudarthrobacter phenanthrenivorans] 
91% 6.00E-50 60% WP_041652569.1 
rifampin ADP-ribosyl transferase 
[Myroides injenensis] 
97% 6.00E-50 56% WP_010257556.1 
rifampin ADP-ribosylating transferase 
[Clostridium clostridioforme] 
92% 6.00E-50 56% WP_002589901.1 
rifampin ADP-ribosyl transferase 
[Flavihumibacter solisilvae] 
89% 7.00E-50 59% WP_039140159.1 
ribosomal subunit interface protein 
[Riemerella anatipestifer] 
97% 8.00E-50 56% WP_064969801.1 
rifampin ADP-ribosylating transferase 
ARR-2 [Collimonas fungivorans] 
93% 8.00E-50 59% WP_061540182.1 
rifampin ADP-ribosyl transferase 
[Spirosoma spitsbergense] 
91% 2.00E-49 60% WP_063881410.1 
rifampin ADP-ribosyl transferase 
[Chryseobacterium angstadtii] 
92% 2.00E-49 57% WP_048508524.1 
rifampin ADP-ribosylating transferase 
[Fluviicola taffensis] 
91% 4.00E-49 57% WP_013687973.1 
ADP-ribosyltransferase  
[Nitratireductor pacificus] 
90% 6.00E-49 58% WP_008599148.1 
rifampin ADP-ribosyl transferase 
[Spirosoma luteum] 
91% 1.00E-48 58% WP_018621553.1 
rifampin ADP-ribosyl transferase 
[Chryseobacterium indologenes] 
89% 1.00E-48 58% WP_062697472.1 
rifampin ADP-ribosyl transferase 
[Pseudarthrobacter sulfonivorans] 
92% 2.00E-48 58% WP_058932937.1 
rifampin ADP-ribosyl transferase 
[Cytophaga aurantiaca] 
90% 2.00E-48 57% WP_018342679.1 
rifampin ADP-ribosyl transferase 
[Phenylobacterium zucineum] 
90% 4.00E-48 60% WP_041373627.1 
rifampin ADP-ribosylating transferase 
[Desulfotomaculum hydrothermale] 
100% 4.00E-48 54% WP_008413283.1 
rifampin ADP-ribosyl transferase 
[Luteibacter rhizovicinus] 
92% 4.00E-48 56% WP_063572277.1 
hypothetical protein 
 [Chryseobacterium soli] 
92% 4.00E-48 54% WP_034710413.1 
hydrolase or acyltransferase of alpha/beta 
superfamily protein 
[Arthrobacter nitrophenolicus] 
94% 7.00E-48 56% WP_009358747.1 
rifampin ADP-ribosyl transferase [Devosia 
riboflavina] 
88% 7.00E-48 58% WP_035078136.1 
rifampin ADP-ribosyl transferase 
[Leptolyngbya boryana] 
89% 7.00E-48 58% WP_026148669.1 
rifampin ADP-ribosyl transferase 
[Chryseobacterium vrystaatense] 
93% 7.00E-48 55% WP_034749533.1 
hypothetical protein  
[Runella zeae] 
90% 8.00E-48 57% WP_028668032.1 
ribosomal subunit interface protein 
[Elizabethkingia anophelis] 
100% 9.00E-48 51% WP_035590937.1 
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hypothetical protein 
 [Chryseobacterium luteum] 
93% 9.00E-48 55% WP_034702130.1 
rifampin ADP-ribosyl transferase 
[Sunxiuqinia dokdonensis] 
90% 1.00E-47 58% WP_053187313.1 
NAD(+)-rifampin ADP-ribosyltransferase 
Arr-4 [Pseudomonas aeruginosa] 
91% 2.00E-47 57% WP_033959319.1 
rifampin ADP-ribosyl transferase 
[Rudanella lutea] 
99% 2.00E-47 52% WP_019990724.1 
rifampin ADP-ribosylating transferase 
ARR-2 [Collimonas pratensis] 
93% 2.00E-47 58% WP_061939301.1 
rifampin ADP-ribosyl transferase 
[Nocardia inohanensis] 
92% 3.00E-47 58% WP_067813926.1 
rifampin ADP-ribosyl transferase 
[Caulobacter henricii] 
89% 4.00E-47 60% WP_035041762.1 
rifampin ADP-ribosyl transferase 
[Pseudoxanthomonas suwonensis] 
86% 5.00E-47 60% WP_037061093.1 
ribosomal subunit interface protein 
[Staphylococcus xylosus] 
94% 1.00E-46 56% WP_039067545.1 
rifampin ADP-ribosyl transferase [Runella 
slithyformis] 
89% 1.00E-46 55% WP_013930076.1 
hypothetical protein  
[Anaeromyxobacter dehalogenans] 
88% 3.00E-46 60% WP_049760209.1 
ribosomal subunit interface protein 
[Herbaspirillum hiltneri] 
90% 3.00E-46 55% WP_053195305.1 
ribosomal subunit interface protein 
[Paucisalibacillus globulus] 
93% 3.00E-46 56% WP_026909123.1 
ribosomal subunit interface protein 
[Rufibacter roseus] 
88% 4.00E-46 53% WP_066621345.1 
hypothetical protein  
[Enterococcus raffinosus] 
90% 5.00E-46 54% WP_010747320.1 
ribosomal subunit interface protein 
[Flexithrix dorotheae] 
89% 6.00E-46 57% WP_063745009.1 
rifampin ADP-ribosyl transferase 
[Dokdonella koreensis] 
88% 6.00E-46 56% WP_067643213.1 
rifampin ADP-ribosyl transferase 
[Sphingomonas sanxanigenens] 
88% 6.00E-46 59% WP_039997119.1 
rifampin ADP-ribosyl transferase 
[Mucilaginibacter gotjawali] 
90% 1.00E-45 56% BAU55424.1 
rifampin ADP-ribosyl transferase 
[Clostridium saccharoperbutylacetonicum] 
90% 2.00E-45 55% WP_015392137.1 
rifampin ADP-ribosylating transferase 
ARR-2 [Klebsiella pneumoniae] 
90% 2.00E-45 57% KYL72167.1 
ADP-ribosylating transferase [Vibrio 
fluvialis] 
91% 2.00E-45 57% ADK38648.1 
By using the amino acid sequence of the rifampicin ADP-ribosyltransferase from Mycobacterium 
smegmatis mc
2
155 (Accession: ABK71231) as a query, the ADP-ribosyltransferase-like proteins of non-
mycobacterial species were identified by systematic BLASTP (non-redundant protein sequences, E-value 
<0.001). The first 100 non-mycobacterial species with the best hits predicted to possess ADP-
ribosyltransferase-like proteins are listed. 
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ADDENDUM 
Personal contribution to chapter 1 
My contribution as first author to this manuscript was as follows: 
 Design of the study. 
 Analysis of the RpoB rifampicin resistance sequence clusters from M. abscessus. 
 Distribution analysis of ADP-ribosyltransferase-like proteins in selected mycobacterial 
species and in non-mycobacterial species. 
 Heterologous expression of MAB_0591 in M. tuberculosis. 
 Generation of M. abscessus MAB_0591 deletion mutant. 
 DST of M. abscessus ΔMAB_0591. 
 DST of C25 modified rifamycin derivatives. 
 Writing of the manuscript. 
 Revision of the manuscript.
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ABSTRACT 
Objectives: Mycobacterium abscessus is innately resistant towards a variety of drugs thereby 
limiting therapeutic options. Bacterial resistance towards aminoglycosides (AGs) mainly is 
conferred by AG-modifying enzymes which often have overlapping activities. Several 
putative AG-modifying enzymes are encoded in the genome of M. abscessus. The aim of this 
study is to investigate the molecular basis underlying AG resistance in M. abscessus. 
Methods: M. abscessus deletion mutants deficient in either of three genes potentially 
involved in AG resistance, aac(2ʹ), eis1 and eis2, were generated by targeted gene 
inactivation, as were combinatorial double and triple deletion mutants. Minimal inhibitory 
concentration (MIC) assays were used to study susceptibility towards a variety of AG drugs 
and towards capreomycin. 
Results: Deletion of aac(2ʹ) increased susceptibility of M. abscessus towards kanamycin B, 
tobramycin, dibekacin and gentamicin C. Deletion of eis2 increased susceptibility towards 
capreomycin, hygromycin B, amikacin and kanamycin B. Deletion of eis1 did not affect drug 
susceptibility. Equally low MICs in wildtype and mutant strains for apramycin, arbekacin, 
isepamicin and kanamycin A indicate that these drugs are not inactivated by either AAC(2') or 
Eis enzymes. 
Conclusions: M. abscessus expresses two distinct AG resistance determinants AAC(2') and 
Eis2 which confer clinically relevant drug resistance. 
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INTRODUCTION 
Mycobacterium abscessus is a rapid growing mycobacterium (RGM) of increasing medical 
importance. This emerging pathogen causes bronchopulmonary infections in individuals with 
cystic fibrosis (CF)
1 
and chronic pulmonary disease, like pneumoconiosis and bronchiectasis.
2
 
It also causes severe infections following surgery, transplantation, tattooing and 
mesotherapy.
3-8
 Treatment of an M. abscessus infection is difficult due to the bacteria’s high 
degree of intrinsic resistance to chemotherapeutic agents.
9
 The pathogen is naturally resistant 
towards many major classes of antibiotics used for treatment of Gram-positive and Gram-
negative bacterial infections, like β-lactams, aminoglycosides (AGs) [kanamycin (B), 
gentamicin C] and macrolides (erythromycin). In addition, it is also resistant towards first-line 
tuberculosis drugs, e.g. isoniazid and rifampicin. M. abscessus has been called an antibiotic 
nightmare
 
since treatment options against M. abscessus infection are more limited than for 
Mycobacterium tuberculosis infection.
10
 While no standard treatment recommendations for 
pulmonary M. abscessus infections have yet been established, current guidelines propose 
administration of an oral macrolide (clarithromycin or azithromycin) for clinical isolates 
susceptible to macrolides and the intravenous AG amikacin in combination with a parenteral 
β-lactam antibiotic, cefoxitin or imipenem.11 AGs and macrolides inhibit protein biosynthesis 
by binding to the small and large ribosomal subunit, respectively. Clinically acquired pan-AG 
and pan-macrolide resistance has been attributed to mutations in ribosomal RNA genes rrs 
and rrl, coding for 16S and 23S rRNA, respectively. Due to the presence of a single ribosomal 
RNA (rrn) operon, corresponding resistance mutations have readily been observed in M. 
abscessus.
12-14
 However, distinct mechanisms have been proposed to be responsible for innate 
AG resistance in M. abscessus.
9,15 
AG antibiotics form a group of hydrophilic molecules, consisting of a characteristic, central 
aminocyclitol linked to one or more amino sugars by pseudoglycosidic bond(s). They inhibit 
prokaryotic protein biosynthesis by binding to the A-site of the 16S rRNA. AGs are active 
against a wide range of aerobic Gram-negative bacilli, staphylococci and mycobacteria. 
Resistance towards AGs is due to low uptake, increased efflux, target modification or enzyme 
mediated drug modification. Originally isolated from microorganisms (mainly Streptomyces 
spp.), semisynthetic derivatives of AGs have been generated to improve pharmacological 
properties of the drugs and to overcome bacterial resistance mechanisms.
16
 The semisynthetic 
amikacin is a cornerstone of M. abscessus infection therapy, while other AGs are not 
frequently used. M. abscessus genome annotation suggests the presence of various AG-
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modifying enzymes such as AG phosphotransferases (APH), AG nucleotidyltransferases 
(ANT) and AG acetyltransferases (AAC).
17
 The individual contribution of these genes to M. 
abscessus AG susceptibility can hardly be predicted due to overlapping specificities.   
Elucidation of gene functions, drug target and host-pathogen interaction heavily relies on 
generation of isogenic mutants. Usually, antibiotic resistance markers are used for primary 
selection of transformants. Tools for genetic manipulation of mycobacteria in general and M. 
tuberculosis in particular, have been developed during the past 2-3 decades.
18
 In contrast, 
attempts for genetic manipulation of M. abscessus have been reported to be very difficult and 
often were unsuccessful
19-21
, although some progress has been made.
22-25
 We recently 
developed genetic tools for M. abscessus
26
 and now exploited them for elucidating intrinsic 
AG resistance mechanisms in the M. abscessus ATCC 19977 type strain. We particularly 
addressed the role of putative AG acetyltransferases on M. abscessus AG and capreomycin 
resistance. We generated single, double and triple mutants of M. abscessus by targeted 
deletion of three genes potentially involved in AG resistance and characterized those mutants 
by phenotypic drug susceptibility testing. Interestingly, a double mutant proved to be 
susceptible towards a wide variety of AGs and towards the peptide antibiotic capreomycin.   
 
MATERIALS AND METHODS 
Bacterial strains and media 
The Escherichia coli laboratory strain XL1-Blue MRF’ (Stratagene, Switzerland) and ER2925 
dam
-
, dcm
-
 were used for cloning and propagation of plasmids. The strains were grown in 
Luria-Bertani (LB) medium containing either of the antibiotics: Ampicillin (120 mg/L), 
kanamycin A (50 mg/L), apramycin (50 mg/L), and hygromycin B (100 mg/L). Antibiotics 
(Sigma-Aldrich, Switzerland) were dissolved in H2O according to the manufacturer’s 
recommendations and stored as a stock solution until usage.  
M. abscessus ATCC 19977 were grown in Middlebrook 7H9-OADC-Tween 80 or LB 
containing either of the antibiotics, if required: kanamycin A (50 mg/L), apramycin (50 
mg/L), isoniazid (32 mg/L). For preparation of electrocompetent cells two cell culture flasks 
each containing 200 mL 7H9-OADC-Tween 80 were inoculated 1:100, incubated at 37 °C 
and gently shaken daily. When OD600 reached 0.4-0.8, cultures were set on ice for 90 minutes. 
Bacteria were harvested by centrifugation, and repeatedly resuspended in ice-cold glycerol 
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(10% v/v) while gradually reducing the volume.
27
 Finally, bacteria were resuspended in 2 mL 
glycerol (10% v/v) and either frozen in liquid nitrogen or directly used for electroporation, as 
we recently described.
26 
Genomic DNA was isolated by phenol-chloroform-isoamyl alcohol 
extraction, as described previously.
28 
 
Generation of vectors 
The apramycin resistance cassette from plasmid pSET152
29
 was PCR amplified (primers 
Apr_F and Apr_R) (see Table S1 for list of primers) and cloned as 1-kbp SpeI fragment into 
SpeI-digested plasmid pMV361
30
 to result in plasmid pMV361-apr. An M. tuberculosis katG 
fragment (2.8-kbp) was PCR amplified (primers KatG_F and KatG_R), saved into pGEM-T-
easy to result in pGEM-T-katG. Subsequently, the 2.8-kbp SwaI-katG-HpaI fragment was 
cloned into HpaI-linearized pMV361-apr to result in pMV361-apr-katG. Removal of 
mycobacteriophage attP/int from plasmid pMV361-apr-katG by XbaI excision and self-
ligation of the vector backbone resulted in the prototype suicide vector pSE-apr-katG into 
which flanking regions of the target genes were cloned.     
 
Disruption of MAB_4395 [aac(2ʹ)] in M. abscessus  
A 1.6-kbp NdeI/NheI fragment of M. abscessus ATCC 19977 from position 4477184 to 
4478794 comprising the 5ʹ flanking sequence and a 1.5-kbp NheI/MluI fragment from 
position 4479125 to 4480674 comprising the 3ʹ flanking sequence of MAB_4395 [aac(2ʹ)] 
were PCR amplified (primers 4395_UP_F, 4395_UP_R and 4395_DW_F, 4395_DW_R) 
using genomic DNA from M. abscessus ATCC 19977. Subsequently, fragments were ligated 
stepwise into saving vector pMCS5 with respective enzymes resulting in sub-cloning vector 
pMCS5-MAB_4395. The region comprising 5ʹ and 3ʹ flanking sequences of aac(2ʹ) was cut 
out with StuI and cloned into HpaI linearized pSE-apr-katG vector to result in knockout 
vector pSE-Δaac(2ʹ). The aac(2ʹ) allele was deleted from M. abscessus ATCC 19977 
chromosome using apramycin for positive and isoniazid for negative selection. Deletion of 
aac(2ʹ) was confirmed by Southern blot analysis of Van91I digested genomic DNA with a 
0.3-kbp 5ʹ aac(2ʹ) probe amplified with primers P_4395_F and P_4395_R. A 2.2-kbp 
fragment from M. abscessus ATCC 19977 from position 4477131 to 4479338 spanning the 
entire aac(2ʹ) gene was amplified with primers C_4395_F and C_4395_R and cloned into 
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HindIII digested pMV361 vector to result in pMV361-aac(2ʹ) complementation vector. M. 
abscessus Δaac(2ʹ) was transformed with pMV361-aac(2ʹ) and control vector pMV361, 
respectively. Genetic complementation was confirmed by Southern blot analysis with the 
same 5ʹ aac(2ʹ) probe. 
 
Disruption of MAB_4124 (eis1) in M. abscessus 
A 1.6-kbp ApaI/NdeI fragment of M. abscessus ATCC 19977 from position 4187416 to 
4189052 comprising the 5ʹ flanking sequence and a 1.7-kbp NdeI/NheI fragment from 
position 4189857 to 4191580 comprising the 3ʹ flanking sequence of MAB_4124 (eis1) were 
PCR amplified (primers 4124_UP_F, 4124_UP_R and 4124_DW_F, 4124_DW_R) using 
genomic DNA from M. abscessus ATCC 19977. Fragments were stepwise cloned with 
corresponding enzymes into saving vectors and subsequently into NotI/XbaI digested vector 
pSE-apr-katG to result in knockout vector pSE-Δeis1. The eis1 allele was deleted from the M. 
abscessus ATCC 19977 chromosome using apramycin positive and isoniazid negative 
selection. Deletion was confirmed by Southern blot analysis using Van91I digested genomic 
DNA and a 0.3-kbp 5ʹ eis1 fragment amplified with primers P_4124_F and P_4124_R.  
 
Disruption of MAB_4532c (eis2) in M. abscessus 
A 1.8-kbp HpaI/Pfl23II fragment of M. abscessus ATCC 19977 from position 4612843 to 
4614693 comprising the 5ʹ flanking sequence and a 1.5-kbp PacI/Pfl23II fragment from 
position 4615391 to 4616869 comprising the 3ʹ flanking sequence of MAB_4532c (eis2) were 
PCR amplified (primers 4532c_UP_F, 4532c_UP_R and 4532c_DW_F, 4532c_DW_R) using 
genomic DNA from M. abscessus ATCC 19977. Fragments were stepwise cloned into vector 
pSE-apr-katG resulting in knockout vector pSE-Δeis2. The eis2 allele was deleted from M. 
abscessus ATCC 19977 chromosome using apramycin positive and isoniazid negative 
selection. Deletion was confirmed by Southern blot analysis with Van91I digested genomic 
DNA and 0.3-kbp 5ʹ eis2 probe amplified with primers P_4532c_F and P_4532c_R. For 
complementation a 1.3 kbp fragment from M. abscessus ATCC 19977 (position 4614320 to 
4615651) spanning the entire eis2 gene was PCR amplified (primers C_4532c_F, 
C_4532c_R) and cloned via HindIII into pJB-apr vector to result in pJB-apr-eis2 
complementation vector. M. abscessus Δeis2 was transformed with pJB-apr-eis2 and control 
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vector pJB-apr, respectively. Genetic complementation was confirmed by Southern blot 
analysis.  
 
MIC assays 
Kanamycin B, tobramycin, dibekacin, arbekacin, gentamicin C [C1 (<45%), C2 (<35%) and 
C1a (<30%)], isepamicin, amikacin, kanamycin A, apramycin, streptomycin, hygromycin B 
and capreomycin were bought from Sigma-Aldrich, CH. Antibiotics were dissolved in H2O 
according to the manufacturer’s recommendations, were filter sterilized, aliquoted into stock 
solutions and stored at -20 °C. MIC determination for M. abscessus strains was done 
according to CLSI guidelines
31
 and basically as we previously described.
26
  
 
RESULTS 
Targeted inactivation of putative AG resistance genes of M. abscessus 
Genome annotation
17
, genome analysis and AG drug susceptibility testing
15
 suggest the 
presence of several putative AG acetyltransferases in M. abscessus. Open reading frame 
MAB_4395 is annotated as a putative AG 2ʹ-N-acetyltransferase [aac(2ʹ)]17, while MAB_4124 
and MAB_4532c show homology to eis. Eis (Enhanced intracellular survival) proteins are 
found in a variety of mycobacterial and non-mycobacterial species.
32-33
 Overexpression of Eis 
(Rv2416c) confers increased kanamycin resistance to M. tuberculosis.
34
 M. abscessus 
MAB_4124 is the closest homologue of M. tuberculosis Rv2416c (33% identity), which we 
therefore name eis1. Interestingly, a second Eis homologue encoded by MAB_4532c is 
present in the M. abscessus genome. In a phylogenetic tree constructed from 29 Eis 
homologues
33
, MAB_4532c (which we name Eis2) is clustered with Eis homologues from the 
non-mycobacterial clade instead of the mycobacterial group, for instance M. abscessus Eis2 
shows 23% identity to Anabaena variabilis Eis. We addressed the role of the three 
acetyltransferases in M. abscessus AG resistance by engineering and characterizing 
corresponding unmarked deletion mutants in M. abscessus type strain ATCC 19977. 
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Table 1. Strains used in this study 
 
 
 
 
 
Strain Description Source 
E. coli XL1-Blue MRF’ Cloning and propagation of plasmids Stratagene 
E. coli ER2925 dam
-
, dcm
- 
Cloning and propagation of plasmids with 
methylase susceptible restriction enzymes 
New England BioLabs 
M. abscessus ATCC 19977 M. abscessus type strain (Ripoll et al., 2009)
17 
M. abscessus Δaac(2') M. abscessus aac(2') deletion mutant; derivative 
of M. abscessus ATCC 19977 
This study 
M. abscessus Δeis1 M. abscessus eis1 deletion mutant; derivative of 
M. abscessus ATCC 19977 
This study 
M. abscessus Δeis2 M. abscessus eis2 deletion mutant; derivative of 
M. abscessus ATCC 19977 
This study 
M. abscessus Δaac(2') Δeis1 M. abscessus aac(2') eis1 double deletion mutant; 
derivative of M. abscessus Δeis1 
This study 
M. abscessus Δaac(2') Δeis2 M. abscessus aac(2') eis2 double deletion mutant; 
derivative of M. abscessus Δaac(2') 
This study 
M. abscessus Δeis1 Δeis2 M. abscessus eis1 eis2 double deletion mutant; 
derivative of M. abscessus Δeis2 
This study 
M. abscessus Δaac(2') Δeis1 
Δeis2 
M. abscessus aac(2') eis1 eis2 triple deletion 
mutant; derivative of M. abscessus Δeis1 Δeis2 
This study 
M. abscessus Δaac(2') 
pMV361-aac(2') 
M. abscessus aac(2') mutant transformed with 
complementation vector pMV361-aac(2') 
This study 
M. abscessus Δaac(2') 
pMV361 
M. abscessus aac(2') mutant transformed with 
pMV361 control vector 
This study 
M. abscessus Δeis2 pJB-apr-
eis2 
M. abscessus Δeis2 mutant transformed with 
complementation vector pJB-apr-eis2 
This study 
M. abscessus Δeis2 pJB-apr M. abscessus Δeis2 mutant transformed with 
control vector pJB-apr 
This study 
 
Flanking fragments of the target genes aac(2ʹ), eis1 and eis2 were cloned into plasmid pSE-
apr-katG to result in suicide vectors pSE-Δaac, pSE-Δeis1 and pSE-Δeis2, respectively. 
These flanking fragments enable homologous recombination of the suicide vector. The 
apramycin resistance cassette of the vector backbone facilitates selection of single crossover 
transformants resulting from vector integration by intermolecular homologous recombination 
at the target locus. Catalase-peroxidase KatG, the activator of the tuberculosis prodrug 
isoniazid
35
, serves as a negative selectable marker since it sensitizes M. abscessus to 
isoniazid. Expression of KatG facilitates screening for deletion mutants resulting from 
resolving the integration of the suicide vector by a second intramolecular homologous 
recombination.
26
 Electrocompetent M. abscessus were transformed and apramycin selection 
and Southern blot analysis were applied to identify single crossover transformants. 
Subsequently, isoniazid counterselection and Southern blot analysis were applied for the 
identification of M. abscessus Δaac(2ʹ), M. abscessus Δeis1 and M. abscessus Δeis2 mutants 
(Figure 1). Deletion mutants showing a phenotype [M. abscessus Δaac(2ʹ) and M. abscessus 
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Δeis2] were transformed with single-copy, i.e. pMV361-based complementation and control 
vectors, respectively (see Table 1 for list of strains and Table 2 for list of plasmids). 
Furthermore, single deletion mutants served as parental strains for construction of double 
deletion mutants by transformation with a second targeting vector. Double deletion mutants, 
M. abscessus Δaac(2') Δeis1, M. abscessus Δaac(2') Δeis2 and M. abscessus Δeis1 Δeis2, 
were confirmed by Southern blot analyses. Finally, by transformation of pSE-Δaac(2') into M. 
abscessus Δeis1 Δeis2, the triple mutant M. abscessus Δaac(2') Δeis1 Δeis2 was constructed 
(Figure 2).   
 
Table 2. Plasmids used in this study 
 
 
 
 
Plasmid Description; selectable marker Source 
pMV361 Integrative E. coli/mycobacterial shuttle vector; Kan
R
 (Stover et al., 1991)
30 
pSET152 Streptomyces vector with apramycin resistance gene 
[aac(3)IV], template for apr amplification; Apr
R
 
(Wilkinson et al., 2002)
29 
pGEM-T-easy PCR saving vector; Amp
R
 Promega 
pMCS5 General cloning vector; Amp
R
 MBio 
pGEM-T-katG Intermediate vector for katG subcloning; Amp
R
 This study 
pMV361-apr Integrative E. coli/mycobacterial shuttle vector; Kan
R
, 
Apr
R
 
This study 
pMV361-apr-katG Derivative of pMV361-apr containing M. tuberculosis 
katG; Kan
R
, Apr
R
, INH
S
 
This study 
pSE-apr-katG Derivative of pMV361-apr-katG deleted for 
mycobacteriophage integrase int and attP; intermediate 
vector used for cloning of Δaac(2'), Δeis1 and Δeis2 
alleles; Kan
R
, Apr
R
, INH
S
 
This study 
pMCS5-MAB_4395 Intermediate vector containing aac(2') flanking 
regions; Amp
R
 
 
pSE-Δaac(2') Suicide vector; derivative of pSE-apr-katG carrying 
Δaac(2') allele; AprR, KanR, INHS 
This study 
pSE-Δeis1 Suicide vector; derivative of pSE-apr-katG carrying 
Δeis1 allele; AprR, KanR, INHS 
This study 
pSE-Δeis2 Suicide vector; derivative of pSE-apr-katG carrying 
Δeis2 allele; AprR, KanR, INHS 
This study 
pMV361-aac(2') Integrative complementation vector for aac(2'), Kan
R
 This study 
pJB-apr Derivative of pMV361 in which the kanamycin 
resistance cassette was substituted by the apramycin 
resistance cassette; Apr
R
 
This study 
pJB-apr-eis2 Integrative complementation vector for eis2; derivative 
of pJB-apr; Apr
R
 
This study 
Kan
R
 = kanamycin resistance cassette; Apr
R
 = apramycin resistance cassette; Amp
R
 = ampicillin resistance 
cassette; INH
S 
= isoniazid susceptibility cassette 
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Figure 1. Genotypic analyses of M. abscessus deletion mutants. (a) General schematic drawing of genotypes and 
recombination events. (b) Southern blot analysis confirms the deletion of aac(2') (MAB_4395) from the genome 
of M. abscessus. Genomic DNA of M. abscessus ATCC 19977 (1), M. abscessus transformant with pSE-
Δaac(2') targeting vector prior to (2) and after KatG-dependent isoniazid-counterselection (3) and after 
transformation of counterselected mutant with pMV361-aac(2') complementation vector (4) was digested with 
Van91I and probed with a fragment from the 5ʹ aac(2') flanking region. Based on M. abscessus genome 
annotation and vector sequence, the pattern is consistent with hybridization to a 2.5-kbp fragment of the wild-
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type (wt) parental strain, to the 2.1-kbp and 2.5-kbp fragments after site-specific homologous recombination 
(single crossover; sco), to a 2.1-kbp fragment of the M. abscessus Δaac(2') mutant (Δ) and to the 2.1-kbp and 
11.2-kbp fragments of the M. abscessus Δaac(2') pMV361-aac(2') complemented mutant strain (C). (c) Southern 
blot analysis confirms the deletion of eis1 (MAB_4124) from the genome of M. abscessus. Genomic DNA of M. 
abscessus ATCC 19977 (1), M. abscessus transformant with pSE-Δeis1 targeting vector prior to (2) and after 
KatG-dependent isoniazid-counterselection (3) was digested with Van91I and probed with a fragment from the 5ʹ 
eis1 flanking region. Based on M. abscessus genome annotation and vector sequence, the pattern is consistent 
with hybridization to a 5.6-kbp fragment of the wild-type (wt) parental strain, to the 4.4-kbp and 7.8-kbp 
fragments after site-specific homologous recombination (sco) and to a 10.4-kbp fragment of the M. abscessus 
Δeis1 mutant (Δ). (d) Southern blot analysis confirms the deletion of eis2 (MAB_4532c) from the genome of M. 
abscessus. Genomic DNA of M. abscessus ATCC 19977 (1), M. abscessus transformant with pSE-Δeis2 
targeting vector prior to (2) and after KatG-dependent isoniazid-counterselection (3) and after transformation of 
counterselected mutant with pJB-apr-eis2 complementation vector (4) was digested with Van91I and probed 
with a fragment from the 5ʹ eis2 flanking region. Based on M. abscessus genome annotation and vector 
sequence, the pattern is consistent with hybridization to a 1.1-kbp fragment of the wild-type (wt) parental strain, 
to the 1.1-kbp and 3.4-kbp fragments after site-specific homologous recombination (sco), to a 4.8-kbp fragment 
of the M. abscessus Δeis2 mutant (Δ) and to the 4.8-kbp and 10.3-kbp fragments of the M. abscessus Δeis2 pJB-
apr-eis2 complemented mutant strain (C). 
 
 
Figure 2. Genealogy of M. abscessus strains used in this study for the construction of single, double and triple 
deletion mutants.  
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Drug susceptibility testing of M. abscessus mutant strains 
Drug susceptibility of M. abscessus strains towards a variety of structurally similar 4,6-
distubstituted AGs (Figure 3) was tested in Cation Adjusted Müller-Hinton Broth. In addition, 
drug susceptibility towards structurally atypical AGs apramycin, hygromycin B and 
streptomycin and towards the peptide antibiotic capreomycin (also inhibiting protein 
biosynthesis by interaction with 16S rRNA A-site) was determined. Growth was judged after 
3, 5, 7 and 12 days of incubation and the MICs were determined. The median MIC values on 
day 5 are listed in Table 3. The median MIC values read at all time points are shown in Table 
S2. A variety of mutant phenotypes was observed. Deletion of aac(2') increased susceptibility 
of M. abscessus towards kanamycin B (64-fold), tobramycin (32-fold), dibekacin (16-fold), 
gentamicin C (4-fold). Deletion of aac(2') did not affect MIC towards arbekacin, isepamicin, 
amikacin, kanamycin A, apramycin, streptomycin, hygromycin B and capreomycin (Table 3). 
The tobramycin, dibekacin and gentamicin C wild-type phenotype was restored upon 
transformation with the complementation vector pMV361-aac(2'), but not by transformation 
with the backbone control vector pMV361 (Table S2). The presence of a kanamycin 
resistance cassette [aph(3')] in the backbone of the complementation vector interfered with 
DST for kanamycin A and B and MICs for these compounds are therefore not reported. 
Deletion of eis1 did not result in a detectable phenotype; MIC towards none of the tested 
antibiotics was altered. Due to the absence of a phenotype, no complementation vector was 
constructed. Deletion of eis2 increased susceptibility of M. abscessus towards several AGs. 
However, the susceptibility pattern of M. abscessus Δeis2 clearly differed from that of M. 
abscessus Δaac(2'). Deletion of eis2 increased susceptibility towards kanamycin B (4-fold), 
amikacin (8-fold), hygromycin B (16-fold) and capreomycin (32-fold). Deletion of eis2 did 
not affect susceptibility towards tobramycin, dibekacin, arbekacin, gentamicin C, isepamicin, 
kanamycin A, apramycin, and streptomycin. Transformation of the Δeis2 mutant with the 
complementation vector pJB-apr-eis2, but not with the vector backbone pJB-apr, restored 
wild-type MIC levels towards amikacin, hygromycin B and capreomycin (Table S2). The 
presence of the apramycin resistance cassette in the backbone of the complementation vector 
interfered with DST for kanamycin (A and B), tobramycin, dibekacin, gentamicin C and 
apramycin, and therefore MIC values for these antibiotics are not reported. Double mutant M. 
abscessus Δaac(2') Δeis1 had the same phenotype as the Δaac(2') single mutant. Double 
mutant M. abscessus Δeis1 Δeis2 had the same phenotype as the Δeis2 single mutant. The M. 
abscessus Δaac(2') Δeis2 double mutant showed increased susceptibility towards kanamycin 
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B, tobramycin, dibekacin, gentamicin C, amikacin, hygromycin B and capreomycin, while 
MICs towards arbekacin, isepamicin, kanamycin A, apramycin and streptomycin were not 
altered. Thus, the phenotype of the Δaac(2') Δeis2 double mutant is a combination of the 
phenotype of the single mutants. The phenotype of the triple Δaac(2') Δeis1 Δeis2 mutant was 
similar to the phenotype of the Δaac(2') Δeis2 double mutant. Together, these data indicate a 
distinct role of aac(2') and of eis2 in intrinsic AG and capreomycin resistance in M. 
abscessus. Notably, AAC(2') and Eis2 prevent antibacterial effects of different subset of AGs. 
The only exception is kanamycin B that is modified by both AAC(2') and Eis2. However, the 
deletion of aac(2') had a stronger effect on kanamycin B susceptibility than deletion of eis2 
(64-fold vs. 4-fold). AAC(2') is more influential than Eis2, since the MIC of the double 
deletion mutant is not further decreased as compared to the aac(2') deletion mutant. Deletion 
of eis1 from the genome of the Δaac(2') Δeis2 mutant did not further increase AG 
susceptibility, indicating a negligible role of Eis1 in M. abscessus intrinsic AG resistance even 
in an aac(2') eis2 double deletion mutant.   
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Figure 3: Structure of 4,6-disubstituted (a-j) and atypical (k-m) AGs used in this study. The aminocyclitol ring is 
shown in red. Black arrows show the 2ʹ-groups of the 4,6-distubstituted AGs (a-j). 
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DISCUSSION 
M. abscessus is a pathogen of increasing medical importance particularly in individuals with 
chronic pulmonary disease. The high level of intrinsic resistance towards many classes of 
antibiotics restricts antibiotic therapy.
9
 Genome annotation
17
, DST and biochemical assays 
predicted a role for a 2'-N-acetyltransferase in M. abscessus AG resistance.
15
 A candidate 
gene eventually responsible for the increased MIC levels towards 2'-amino-AGs, MAB_4395 
[aac(2')] was inactivated by targeted gene deletion. Comparison of wildtype and mutant strain 
by phenotypic DST demonstrated a decreased MIC of the mutant towards a variety of drugs 
characterized by a 2'-amino-group (kanamycin B, tobramycin, dibekacin, gentamicin C). 
Kanamycin A which differs from kanamycin B by a single structural feature (2'-OH-group 
instead of a 2'-amino-group) has a lower MIC against the wildtype than kanamycin B and its 
MIC is not further decreased by aac(2') deletion. These data corroborate the hypothesis that 
MAB_4395 encodes a functional AG 2'-N-acetyltransferase which renders M. abscessus 
relatively resistant towards several AGs with a 2'-amino-group. Amikacin is protected from 
AAC(2') modification due to the presence of a OH-group at 2'-position. Actually, amikacin is 
a derivative of kanamycin A, but with an L-hydroxyaminobutyryl amide (L-HABA) side 
chain at the position 1 of the 2-deoxystreptamine core. Tobramycin (3'-deoxy-kanamycin B) 
is inert to modification by 3'-phosphotransferases, but susceptible towards modification by 
AAC(2'). This is indicated by the observation that the kanamycin B and tobramycin MICs are 
similarly decreased in the Δaac(2') mutant strain as compared to the parental strain. Since 
tobramycin is not a substrate for the 3'-AG-phosphotransferase [APH(3')] (which is encoded 
on the backbone of the complementation vector pMV361-aac(2')] restoration of the 
tobramycin phenotype could be addressed by transformation with the complementation 
vector. Phenotypic complementation was observed indicating that deletion of aac(2') is 
responsible for increased tobramycin susceptibility of the mutant. MIC towards arbekacin is 
similarly low in wildtype and Δaac(2') mutant and also similar to the MIC of dibekacin of the 
Δaac(2') mutant, while the MIC of the wildtype towards dibekacin is much higher. Dibekacin 
(3',4'-dideoxy-kanamycin B) differs from arbekacin at position 1 of the 2-deoxystreptamine 
core; there arbekacin carries an L-HABA chain, which obviously protects from AAC(2') 
activity.  
Gentamicin C is not a pure component, but a mixture of different subclasses (C1, C2 and 
C1a). C-type gentamicin subgroups carry a 2'-NH2-group. In contrast, B-type gentamicin 
carries a 2'-OH-group. Isepamicin is a derivative of gentamicin B with an L-HABA side chain 
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at position 1 of the 2-deoxystreptamine core. The MIC of the wildtype towards isepamicin is 
lower than towards gentamicin C, while both compounds have similarly (low) MICs against 
the Δaac(2') mutant strain. These findings may be explained by the enzymatic modification of 
gentamicin C by the AAC(2') activity present in the wild-type strain. Taken together, 
comparison of the MICs of wildtype and Δaac(2') mutant indicates that AAC(2') confers 
resistance to drugs carrying a 2'-NH2-group, unless the position 1 of the 2-deoxystreptamine 
core is modified with a L-HABA chain (compare: dibekacin, arbekacin). Neither 
deoxygenation at 3' nor di-deoxygenation at positions 3' and 4' (compare kanamycin B with 
tobramycin and dibekacin, respectively) prevent M. abscessus AAC(2')-mediated drug 
resistance mechanisms. Approximately 10-fold decrease in MIC towards gentamicin C and 
tobramycin and even higher decrease in MIC towards dibekacin were also seen upon genetic 
inactivation of Mycobacterium smegmatis aac(2').
36
  
The M. abscessus Δeis1 mutant did not show any phenotype and therefore does not contribute 
to AG resistance, at least not during in vitro growth. Expression studies and biochemical 
assays would be required to address the physiological and enzymatic function of Eis1. It may 
be hypothesized that promoter up mutations might increase AG resistance. This hypothesis 
could also be addressed by transformation of wild-type strains with multi-copy vectors 
containing eis1. However besides AAC(2')-mediated AG resistance, M. abscessus possess at 
least a second mechanism of AG resistance which is mediated by Eis2. The Δeis2 mutant 
showed increased susceptibility towards the peptide antibiotic capreomycin and towards a 
distinct and more heterogeneous group of AGs: kanamycin B, amikacin, hygromycin B. Eis 
proteins of different origin have been shown to have multiple AG- and capreomycin-
acetylating activities, for example M. tuberculosis and M. smegmatis Eis tri-acetylate neamine 
in a sequential manner, first at the 2'-, then at the 6'-, and finally at the 1-position. The number 
of acetylations depends on the AG itself, but also on the biological origin of the enzyme. Up 
to four acetyl residues may be transferred to tobramycin by M. tuberculosis Eis and M. 
smegmatis Eis, respectively.
33,37-38
 Hygromycin is mono- and di-acetylated by M. smegmatis 
and M. tuberculosis Eis, respectively. Apramycin is di-acetylated by M. smegmatis, but is not 
a substrate for M. tuberculosis Eis. M. abscessus Eis2 does not inactivate apramycin (identical 
MIC of wildtype and Δeis2 mutant), although this does not exclude that apramycin is an M. 
abscessus Eis2 substrate. Corresponding acetylations might just not affect antibacterial 
activity. A combined application of an AAC(2') inhibitor together with specific NH2-AGs 
(e.g. kanamycin B and gentamicin C) could enhance the activity of these AGs. Administration 
of an Eis2 inhibitor could enhance the activity of capreomycin and amikacin, the latter being a 
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cornerstone for treatment of M. abscessus infections.
39
 As opposed to several 2-
deoxystreptamine AGs, streptomycin MICs in the mutant strains remained at the high wild-
type MIC levels, pointing to a distinct streptomycin resistance mechanism in M. abscessus. 
Our study demonstrates that apramycin, an AG with little ototoxicity
40
, arbekacin, isepamicin 
and kanamycin A exhibit excellent in vitro activities against M. abscessus ATCC 19977 type 
strain and that the activity of these drugs is not affected by AAC(2') and Eis proteins, 
respectively. Our data further support MIC testing of these aminoglycosides against a broader 
set of M. abscessus clinical isolates.
15
 The results from the suggested in vitro studies may 
provide a rational basis for designing clinical trials aiming at implementation of improved 
treatment regimens against one of the most drug resistant pathogens, M. abscessus. 
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SUPPLEMENTARY DATA 
Table S1. Primers used in this study 
Name Description Sequence 
Apr_F Forward primer for amplification of 
apramycin resistance cassette from 
pSET152 with SpeI linker 
GGACTAGTAGGATCTTCACCTAG
ATCCTT 
Apr_R Reverse primer for amplification of 
apramycin resistance cassette from 
pSET152 with SpeI linker 
TTACTAGTAACGTCATCTCGTTCT
CCGCT 
KatG_F Forward primer for amplification of M. 
tuberculosis katG with SwaI linker 
CTGGTATTTAAATAGGCTGATCCA
CCC 
KatG_R Reverse primer for amplification of M. 
tuberculosis katG with HpaI linker 
GGAGTTAACTCAACCCGAATCAG
C 
4395_UP_F Forward primer for amplification of 5' 
flanking region of aac(2') (i.e. 
MAB_4395) with NdeI linker 
AATCATATGGAACGAACCGACTT
ATACACAGGCG 
 
 
4395_UP_R Reverse primer for amplification of 5' 
flanking region of aac(2') (i.e. 
MAB_4395) with NheI linker 
AATGCTAGCGACGGTTGGCATAT
TGGACACAGC  
 
4395_DW_F Forward primer for amplification of 3' 
flanking region of aac(2') (i.e. 
MAB_4395) with NheI linker 
AATGCTAGCTACGAACTGGGGGC
GTTGAGTG 
 
 
4395_DW_R Reverse primer for amplification of 3' 
flanking region of aac(2') (i.e. 
MAB_4395) with MluI linker 
AATACGCGTGGTGTCCCTGACCA
CCGAGCG  
 
C_4395_F Forward primer for amplification of 
aac(2') (i.e. MAB_4395) with HindIII 
linker for cloning into 
complementation vector 
CGAAGCTTGTGGAAATTGTGATG
TTGCC 
 
C_4395_R Reverse primer for amplification of 
aac(2') (i.e.  MAB_4395) for cloning 
into complementation vector with 
endogenous HindIII site 
GCAAGCTTGTCATCACCAGCCGT 
 
P_4395_F Forward primer for amplification of 
aac(2') (i.e. MAB_4395) hybridization 
probe 
TATGACGGCCTCGATCTCGAAGA 
P_4395_R Reverse primer for amplification of 
aac(2') (i.e. MAB_4395) hybridization 
probe 
ATCGAGATCCCAGATGACGGTG
T 
4124_UP_F Forward primer for amplification of 5' 
flanking region of eis1 (i.e. 
MAB_4124) with ApaI linker  
AAAGGGCCCATTCCCGTTCAACA
TCCTGCCG 
4124_UP_R Reverse primer for amplification of 5' 
flanking region of eis1 (i.e. 
MAB_4124) with NdeI linker 
TAACATATGGCCCAAATACCGCC
CTAATTCTAACA 
4124_DW_F Forward primer for amplification of 3' 
flanking region of eis1 (i.e. 
MAB_4124) with NdeI linker 
AAACATATGACCCTCCTCCCACA
CAACGC 
4124_DW_R Reverse primer for amplification of 3' AATGCTAGCTCACCGATCTGGAC
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flanking region of eis1 (i.e. 
MAB_4124) with NheI linker 
GAGGATG 
P_4124_F Forward primer for amplification of 
eis1 (i.e. MAB_4124) hybridization 
probe 
CTCAACGCGAATACATCTCG  
P_4124_R Reverse primer for amplification of 
eis1 (i.e. MAB_4124) hybridization 
probe 
GAATTCCACACTGCCGCTGG 
4532c_UP_F Forward primer for amplification of 5' 
flanking region of eis2 (i.e. 
MAB_4532c) with HpaI linker 
AAGCGTGTTAACGACGAGCAAAA
AC  
 
4532c_UP_R Reverse primer for amplification of 5' 
flanking region of eis2 (i.e. 
MAB_4532c) with Pfl23II and PacI 
linker 
AGCATCGTACGAATGCTTAATTAA
TCTGGAATGTGTTGTGAGCGA 
 
4532c_DW_F Forward primer for the amplification 
of 3' flanking region of eis2 (i.e. 
MAB_4532c) with PacI linker 
GAATTTAATTAAGCCACCCACTTT
T 
4532c_DW_R Reverse primer for amplification of 3' 
flanking region of eis2 (i.e. 
MAB_4532c) with Pfl23II linker 
AATGCCGTACGGATGTCAACGCA
GCCCCCAA 
C_4532c_F Forward primer for amplification of 
eis2 (i.e. MAB_4532c) 
complementation fragment with 
HindIII linker 
GCAAGCTTTCGCGACAACTAGAA 
C_4532c_R Reverse primer for amplification of 
eis2 (i.e. MAB_4532c) 
complementation fragment with 
HindIII linker 
CGAAGCTTCGGTCCACACAGTTG
T 
 
P_4532c_F Forward primer for amplification of 
eis2 (i.e. MAB_4532c) hybridization 
probe 
CTAGAAGTCGTCGGGCGCAC 
P_4532c_R Reverse primer for amplification of 
eis2 (i.e. MAB_4532c) hybridization 
probe 
CGCCGCTGACGTGGATGTG 
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ADDENDUM 
Personal contribution to chapter 2 
My contribution as first author to this manuscript was as follows: 
 Design of the study. 
 Generation of all M. abscessus double and triple deletion mutants. 
 Generation of M. abscessus Δeis2 pJB-apr-eis2 and M. abscessus Δeis2 pJB-apr 
strains. 
 Drug susceptibility testing of M. abscessus strains. 
 Discussion of the results. 
 Writing of the manuscript. 
 Revision of the manuscript.
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ABSTRACT 
Objectives: Limited treatment options available for M. abscessus infections include the 
parenteral β-lactam antibiotics cefoxitin and imipenem, which show moderate in vitro 
activity. Other β-lactam antibiotics (except meropenem) have no considerable in vitro 
activity, due to their rapid hydrolysis by a broad-spectrum β-lactamase (Bla_Mab). We here 
addressed the impact of β-lactamase production and β-lactam in vitro stability on M. 
abscessus MIC results and determined the epidemiological cut-off (ECOFF) values for 
cefoxitin, imipenem and meropenem.  
Methods: By liquid-chromatography high-resolution mass spectrometry (LC-HRMS), we 
assessed the in vitro stability of cefoxitin, imipenem and meropenem. M. abscessus ATCC 
19977 strain and its isogenic blaMab deletion mutant were used for MIC testing. Based on MIC 
distributions of M. abscessus clinical strains, we determined ECOFFs of cefoxitin, imipenem 
and meropenem.  
Results: A functional Bla_Mab increased MICs of penicillins, ceftriaxone and meropenem. 
LC-HRMS data showed significant degradation of cefoxitin, imipenem and meropenem 
during standard antibiotic susceptibility testing procedures. MIC, MIC50 and ECOFF values 
of cefoxitin, imipenem and meropenem are influenced by incubation time. 
Conclusions: The results of our study support administration of imipenem, meropenem and 
cefoxitin, for treatment of patients infected with M. abscessus. Our findings on in vitro 
instability of imipenem, meropenem and cefoxitin explain the problematic correlation 
between in vitro susceptibility and in vivo activity of these antibiotics and question the clinical 
utility of susceptibility testing of these chemotherapeutic agents.  
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INTRODUCTION 
Mycobacterium abscessus is a dreadful and arduous to treat mycobacterial pathogen with 
high-level innate resistance to most commercially available antibiotics, including the 
antituberculous agents.
1-5
 Clinically relevant cases are predominantly associated with 
pulmonary infections in patients with cystic fibrosis or bronchiectasis and disseminated 
disease in immunocompromised individuals.
2-4
 M. abscessus is also highly resistant to 
disinfectants and therefore, it ordinarily causes skin and soft tissue infections following plastic 
surgery, tattooing or body piercing.
3,5-8
 Several healthcare-associated outbreaks of M. 
abscessus infections, that have been reported worldwide, highlight the increasing medical 
importance of this multidrug-resistant pathogen and the urgent need for reliable medication 
strategies.
3-4,9
  
As M. abscessus clinical isolates are uniformly resistant to standard chemotherapeutic agents, 
so far, no reliable antibiotic regimen for M. abscessus pulmonary infections has been 
established. Antibiotic administration is empirical and heavily relies on in vitro antibiotic 
susceptibility testing (AST) by broth microdilution and definitive subspecies identification.
3,10
 
The clinical importance of M. abscessus subspecies identification (M. abscessus subsp. 
abscessus, M. abscessus subsp. bolletii and M. abscessus subsp. massiliense) is attributed to 
the fact that, M. abscessus subsp. abscessus and M. abscessus subsp. bolletii, have a 
functional inducible erythromycin ribosome methyltransferase gene [erm(41)] which confers 
macrolide resistance, whereas M. abscessus subsp. massiliense has a nonfunctional erm(41) 
leading to macrolide susceptibility and thereby, M. abscessus subsp. massiliense infections 
have more favorable prognosis and treatment outcomes.
10-18
 The American Thoracic Society 
(ATS) recommends for the treatment of M. abscessus lung infections a combination therapy 
of an oral macrolide (clarithromycin or azithromycin) for clinical isolates susceptible to 
macrolides and the intravenous aminoglycoside drug amikacin, administered together with a 
parenteral β-lactam antibiotic, cefoxitin or imipenem.3,19-21 However, with the exception of 
the macrolide class, very limited data are present in the literature concerning the correlation 
between AST and the clinical efficacy of these recommended antimycobacterial drugs.
22
 The 
clinical relevance of AST remains a controversy, particularly on account of technical 
problems associated with AST methods, reproducibility of AST results, significant 
discrepancies between in vitro susceptibility and in vivo activity of a given drug, solubility 
and stability issues of the drugs used.
23
 Ideally, clinicians could take advantage of AST for M. 
abscessus, when the in vitro susceptibility to a drug is consistent with a clinically achievable 
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drug exposure in vivo, resulting in favourable treatment outcomes. Accordingly, clinical 
susceptibility breakpoints (CBP) must represent minimal inhibitory concentration (MIC) 
distributions and zone diameter distributions of wild-type and resistant strains, resistance 
mechanisms, dosing regimens, drug pharmacokinetics, pharmacodynamics and 
epidemiological cut-off values (ECOFFs) and must allow prediction of treatment outcomes.
22-
25
 The Clinical and Laboratory Standards Institute (CLSI) is the only organization worldwide 
that has published AST guidelines for rapid growing mycobacteria (RGM)
24
 recommending 
susceptibility testing of amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline or 
minocycline, imipenem, linezolid, moxifloxacin, trimethoprim-sulfamethoxazole and 
tobramycin.
25
 The breakpoint concentrations for these antibiotics have nonetheless been set 
on the basis of in vitro driven studies and their efficacy (except the new drugs linezolid and 
tigecycline) has been clinically evaluated by Wallace et al. principally in patients with 
extrapulmonary disease.
26 
 To date, the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST), has not officially announced guiding principles for nontuberculous 
mycobacteria (NTM) susceptibility testing. 
Frequently used therapeutics for M. abscessus infections are the parenteral β-lactam 
antibiotics cefoxitin and imipenem
24
, which have moderate in vitro activity, with MIC values 
reported by Dubée et al. for M. abscessus subsp. abscessus CIP 104536 of 32 and 8 mg/L, 
respectively.
27
 Meropenem, an ultrabroad-spectrum carbapenem closely related to 
imipenem
28
, displayed a lower MIC value (16 mg/L) than cefoxitin against M. abscessus 
subsp. abscessus CIP 104536.
27
 Most of the other β-lactam antibiotics have no considerable in 
vitro activity due to their rapid hydrolysis by a broad-spectrum class A β-lactamase, encoded 
by MAB_2875, namely Bla_Mab, which was reported as the major determinant of β-lactam 
resistance in M. abscessus.
27,29
 Determination of the kinetic parameters of this enzyme 
revealed that it can slowly hydrolyze imipenem and meropenem, while cefoxitin hydrolysis 
by Bla_Mab is immensely slow, as the methoxy group at cefoxitinʼs β-lactam ring was 
predicted to block the activity of class A β-lactamases.27,29-30  
As imipenem, meropenem and cefoxitin are known to have limited in vitro stability
31
, we 
assessed by liquid-chromatography high-resolution mass spectrometry (LC-HRMS) the in 
vitro stability of these β-lactams and by exploiting a blaMab deletion mutant that we generated, 
we addressed the biological effect of β-lactam stability and β-lactamase production on MIC 
testing results after different periods of incubation. The direct impact of β-lactam stability on 
AST testing was further addressed by MIC determination of fresh and pre-incubated β-lactam 
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antibiotics towards the ampicillin susceptible Escherichia coli XL1-Blue MRF’ strain. What 
is more, based on MIC distributions of M. abscessus clinical strains, mainly isolated from 
respiratory samples, we estimated ECOFFs for cefoxitin, imipenem and meropenem. Our 
results show that MIC, MIC50 and ECOFF values of cefoxitin, imipenem and meropenem are 
severely influenced by stability issues, thereby questioning the clinical utility of AST towards 
cefoxitin, imipenem and meropenem, but not the use of these antibiotics in patients with M. 
abscessus infections. 
 
MATERIALS AND METHODS 
Bacterial strains and growing conditions 
(i) Escherichia coli strains were cultivated in Luria-Bertani (LB) medium or on LB agar 
plates, when necessary, containing either ampicillin (120 mg/L) or apramycin (50 mg/L), at 
37 °C, overnight. For E. coli MIC testing and all cloning steps when constructing the blaMab 
deletion vector pSE-katG-aac(3)IV-ΔMAB_2875, E. coli XL1-Blue MRF’ (Stratagene, 
Switzerland) was used. (ii) Mycobacterium abscessus strains were grown in Middlebrook 
7H9-OADC-Tween 80 liquid medium or on LB agar plates, when needed, containing either 
apramycin (50 mg/L) or isoniazid (32 mg/L), at 37 °C for 5 days. The M. abscessus ATCC 
19977 type strain, M. abscessus ΔblaMab mutant strain and 62 clinical isolates of M. abscessus 
(33 M. abscessus subsp. abscessus, 17 M. abscessus subsp. bolletii and 12 M. abscessus 
subsp. massiliense isolates) were used throughout this study. The M. abscessus clinical 
isolates were mainly isolated from respiratory samples that were received at the Swiss 
National Center for Mycobacteria within the years 2007-2014. 
 
Definitive subspecies identification of clinical isolates 
Subspecies identification of M. abscessus isolates (M. abscessus subsp. abscessus, M. 
abscessus subsp. bolletii and M. abscessus subsp. massiliense) was based on the 16S rRNA, 
rpoB and erm(41) gene sequences.
12-14,32-33
 Subspecies attribution for M. abscessus complex 
isolates was performed according to Tortoli et al.
12
 The obtained sequences were analyzed 
with the use of Lasergene SeqMan software (DNASTAR, USA), the SmartGene IDNS 
mycobacteria and rpoB databases (SmartGene, Switzerland), and the BLAST algorithm 
(http://blast.ncbi.nlm.nih.gov).  
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Antibiotics 
Imipenem, meropenem, cefoxitin, ceftriaxone, ceftazidime, penicillin G, ampicillin, 
amoxicillin, amikacin, apramycin and isoniazid were bought from Sigma-Aldrich, 
Switzerland. All compounds were dissolved in H2O, according to the manufacturer’s 
recommendations, were filter sterilized, aliquoted into stock solutions of 3 to 50 g/L and 
finally stored at -20 °C. 
 
Deletion of MAB_2875 in M. abscessus  
An 1.4-kbp HpaI/Pfl23II fragment from position 2926650 to 2928011 (5ʹ blaMab flanking 
sequence) and an 1.5-kbp Pfl23II/Pfl23II fragment from position 2928642 to 2930147 (3ʹ 
blaMab flanking sequence) were PCR amplified using genomic DNA from M. abscessus 
ATCC 19977 (5ʹ-GAATTAGTTAACCAGGTGTGATCCAGATGCCCG-3ʹ, 5ʹ-
GAATTTCGTACGGGCCGCCGAAATCCTTTTCC-3ʹ and 5ʹ-
GAAATACGTACGCCATCGTGATGGCGGTACTCAC-3ʹ, 5ʹ-
GAATTTCGTACGGTGTCTACCAGTCCTTGCACACC-3ʹ, respectively) and cloned into 
the pSE-katG-aac(3)IV vector with corresponding enzymes, resulting in the blaMab deletion 
vector pSE-katG-aac(3)IV-ΔMAB_2875. M. abscessus blaMab deletion mutant was generated 
using a double selection strategy described previously in detail by Rominski et al.
34-35 
In brief, 
pSE-katG-aac(3)IV-ΔMAB_2875 was transformed into electrocompetent M. abscessus ATCC 
19977. 100 μL competent cells were mixed with 1-2 μg plasmid DNA (supercoiled) and 
electroporated in a BioRad Gene pulser II using 4 mm gap electroporation cuvettes and the 
settings: 2.5 kV, 1000 Ohms and 25 μF.36 Cells were resuspended after electroporation in 0.9 
mL of 7H9-OADC-Tween 80 liquid medium and incubated for 5 h at 37 °C. Proper dilutions 
were eventually plated on selective agar and after 5 days of incubation, single colonies were 
picked and restreaked on LB agar plates with appropriate antibiotics. Transformants were 
selected on LB agar plates containing apramycin and identified by aac(3)IV colony PCR 
(primers: 5ʹ-CACCTTCTTCACGAGGCAGACCTC-3ʹ and  5ʹ-
GGTCTGACGCTCATGGAACTAGTAGG-3ʹ). Isolation of genomic DNA was performed 
by phenol-chloroform-isoamyl alcohol extraction as described previously
37
 and single 
crossover transformants were confirmed by Southern blot analysis with a 0.45-kbp SacI 3ʹ 
blaMab DNA probe and subjected to counter-selection on LB agar plates containing isoniazid. 
Single colonies were screened for deletion of MAB_2875 by PCR (primers: 5ʹ-
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GTACACCGTCTTCGGGACG-3ʹ and 5ʹ-GAAAGTGCGAGTACGCGTCTG-3ʹ) and their 
genotype was finally verified by Southern blot analysis using the same 0.45-kbp SacI 3ʹ 
blaMab DNA probe. In this way, a 0.63-kbp region of the MAB_2875 was deleted from the 
chromosome of M. abscessus ATCC 19977. 
 
Nitrocefin test 
For the detection of β-lactamase production in M. abscessus ATCC 19977 type strain and the 
ΔblaMab mutant strain we performed chromogenic nitrocefin test (Becton Dickinson, USA). 
Tubes containing (i) pure nitrocefin solution, (ii) nitrocefin solution inoculated with 5 
colonies of M. abscessus ATCC 19977 type strain and (iii) nitrocefin solution inoculated with 
5 colonies of M. abscessus ΔblaMab mutant, were incubated for 1 h at room temperature before 
a photo was taken. 
 
MIC assays 
MIC assays were performed with the microdilution method and according to the CLSI 
guidelines,
25 
but with incubation of the 96-well microtiter plates at 37 °C, as described 
previously.
34-35
 Directly after the preparation of the antibiotic stock solutions, working 
solutions were prepared by diluting the corresponding stock solutions in Cation-Adjusted 
Müller-Hinton Broth (CAMHB; pH 7.4) (Becton Dickinson, Switzerland) to a concentration 
of 512 mg/L (final antibiotic concentration used for AST; 256 mg/L) and were subsequently 
stored at -80 °C. Shortly before the conduction of a MIC experiment (day 0), working 
solutions were thawed for the first time and were directly used. Alternatively, working 
solutions were thawed and pre-incubated for 1 to 7 days at 37 °C and their inhibitory effect 
was compared to freshly thawed antibiotics. Two-fold serial dilutions of the freshly thawed 
(and pre-incubated: for the pre-incubation MIC experiments) working solutions were prepared 
using CAMHB in sterile 96-well microtiter plates (Greiner Bio-One, Switzerland). Each 96-
well microtiter plate included a positive growth control lacking antibiotic and a sterile 
negative control containing only CAMHB. To achieve a final inoculum titer of 1-5 x 10
5
 
cfu/mL, while final volume per well was 100 μL, bacterial suspensions of strains with smooth 
or rough phenotypes were adjusted to a McFarland standard of 0.5 and 3.0, respectively, and 
subsequently diluted in CAMHB. The proper titer of the inocula was confirmed by obtaining 
cfu counts on LB agar plates. MIC values were assessed by visual inspection after incubation 
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at 37 °C for 16 h for E. coli strains and 3, 5, 7 and 12 days for M. abscessus. MIC assays 
towards E. coli, M. abscessus ATCC 19977 and M. abscessus blaMab deletion mutant were 
conducted in triplicates. MIC assays towards M. abscessus complex clinical isolates were 
performed once.  
 
LC-HRMS assays 
In vitro antimicrobial stability of cefoxitin, imipenem and meropenem was evaluated using 
CAMHB and the maximum final antibiotic concentration used for AST (256 mg/L). A 
different test tube was prepared for each antibiotic and for every reading time point, i.e. 3, 5, 7 
and 12 days. A day 0 control was used to define the 100% relative antibiotic concentration. 
The antibiotic containing test tubes were incubated under the same temperature conditions as 
the microtiter plates used for AST (37 °C). Cefoxitin, imipenem and meropenem were 
quantified by liquid-chromatography high-resolution mass spectrometry (LC-HRMS) on a Q 
Exactive hybrid instrument (Thermo Fisher, Switzerland). Samples were precipitated using a 
precipitation solution consisting of methanol/acetonitrile 80/20 v/v, containing the 
corresponding stable-isotope labelled internal standards. After centrifugation at 11.700 x g for 
10 min at 4 °C, 10 µL of the clear supernatant were injected into the turbulent flow online 
extraction system. As extraction column, a Cyclone column (50 x 0.5 mm) and for analytical 
chromatography, a Hypersil Gold C8 column (100 x 3 mm), were used. Mobile phases 
consisted of 10 mM ammonium acetate in water + 0.1% formic acid and 10 mM ammonium 
acetate in methanol/acetonitrile 50/50 v/v + 0.1% formic acid. Samples were analyzed in 
positive heated electrospray ionization mode and detection was done in full-scan mode with a 
resolution of 70000 full width at half maximum (calculated for m/z 200).
 
 
ECOFF determination  
MIC data from 62 M. abscessus complex clinical isolates were collected and the resistance 
population analysis charts were calculated using the integrated histographical analysis tool of 
Microsoft Excel. Median MIC50 values of the M. abscessus complex clinical strains against 
cefoxitin, imipenem and meropenem were calculated using SPSS software. All ECOFF values 
were determined by the eye-ball method.
38-39 
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RESULTS AND DISCUSSION 
Generation of M. abscessus MAB_2875 deletion mutant  
Similarly to our previously published techniques
34-35
, we intended to generate an M. abscessus 
ΔMAB_2875 mutant, which would enable us to directly address the role of the β-lactamase 
production of M. abscessus on MIC testing results for β-lactam antibiotics. The blaMab 
deletion mutant was constructed by transformation of M. abscessus ATCC 19977 with 
plasmid pSE-katG-aac(3)IV-ΔMAB_2875 applying apramycin positive selection40 and a katG-
dependent isoniazid counterselection strategy (Figure 1a).
34-35 
Deletion of MAB_2875 was 
confirmed by Southern blot analysis (Figure 1b). While this study was ongoing, a 
ΔMAB_2875 mutant was also generated by Dubée et al.27, but with different cloning, genetic 
manipulation and selection strategies. 
 
Figure 1. Genotypic analyses of M. abscessus blaMab locus. (a) Schematic drawing of genotypes and 
recombination events. (b) Southern blot analysis confirmed the deletion of MAB_2875 from the genome of M. 
abscessus. Genomic DNA of M. abscessus ATCC 19977 (1) and M. abscessus transformant with pSE-katG-
aac(3)IV-ΔMAB_2875 targeting vector after KatG-dependent isoniazid-counterselection (2) was digested with 
SacI and probed with a 0.45-kbp fragment from the 3ʹ blaMab flanking region. Based on M. abscessus genome 
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annotation and vector sequence, the pattern is consistent with hybridization to a 4.0-kbp fragment of the wild-
type (wt) parental strain and to a 3.4-kbp fragment of the M. abscessus ΔblaMab mutant (Δ).  
 
M. abscessus blaMab deletion mutant is deficient in β-lactamase production 
To assess the β-lactamase production of M. abscessus ΔblaMab mutant, we performed a 
chromogenic nitrocefin test. The cephalosporin nitrocefin changes colour from yellow to red, 
in the presence of β-lactamases, that hydrolyze the amide bond in its β-lactam ring.41 As 
Figure 2 shows, the tube containing yellow pure nitrocefin solution did not change colour. 
The tube containing nitrocefin solution inoculated with M. abscessus ATCC 19977, changed 
colour and became red, while the tube containing nitrocefin solution inoculated with the M. 
abscessus ΔblaMab mutant stayed yellow, confirming that the M. abscessus blaMab deletion 
mutant is deficient in β-lactamase production. These results align with the findings from 
Dubée et al.
27
, who reported Bla_Mab as the single determinant of β-lactam resistance in M. 
abscessus. 
 
Figure 2. Chromogenic nitrocefin solution (NCF) test results after incubation for 1 h at 37 °C. (a) Tube 
containing pure nitrocefin solution. (b) Tube containing nitrocefin solution inoculated with M. abscessus ATCC 
19977 wild type. (c) Tube containing nitrocefin solution inoculated with M. abscessus ΔblaMab mutant. 
 
AST of M. abscessus ΔMAB_2875  
In order to explore the role of Bla_Mab in M. abscessus β-lactam resistance, MIC values of 
M. abscessus ATCC 19977 type strain and M. abscessus ΔblaMab mutant were determined 
with the microdilution method for the β-lactam antibiotics, imipenem, meropenem, cefoxitin, 
ceftriaxone, ceftazidime, penicillin G, ampicillin, amoxicillin, and a control antibiotic from 
the class of aminoglycosides, i.e. amikacin (Table 1). As formerly reported
27
, M. abscessus 
ATCC 19977 was highly resistant to all β-lactam antibiotics tested except imipenem, 
CHAPTER 3 
 
90 
 
meropenem and cefoxitin. Deletion of blaMab significantly reduced the MIC values of all 
penicillins tested (penicillin G, ampicillin, amoxicillin) and the cephalosporin ceftriaxone. 
MIC values of ≥256 mg/L of the oxyimino-cephalosporin ceftazidime towards both M. 
abscessus ATCC 19977 and M. abscessus ΔblaMab mutant suggest that ceftazidime is not 
active against M. abscessus. Cefoxitin MIC values of 32 mg/L (day 3) for both the M. 
abscessus ATCC 19977 and ΔblaMab mutant (Table 1) agree with earlier reported data
27
, 
corroborating previous molecular modeling and structural analyses
42 
which delineated that 
substitutions of the β-lactam ring by a methoxy group in cefoxitin inhibits the activity of class 
A β-lactamases.30 As expected, amikacin MICs were independent of the bla genotype.  
 
 
Table 1. AST results of M. abscessus wildtype and ΔblaMab mutant
* 
 
 
 
 
 
 
 
 
 
 
To date, none of the recent studies on β-lactam susceptibility testing towards M. abscessus 
CIP 104536 and M. abscessus ΔblaMab mutant has reported MIC data obtained after 3 days of 
incubation.
27,29-30,43-44
 Indeed, CLSI guidelines
25
 for imipenem MIC testing against RGM 
recommends maximum incubation period of 3 days and state that “the reported breakpoints 
for imipenem are considered tentative”. Our observation that imipenem, meropenem and 
cefoxitin MIC values rise substantially with the incubation time for both the M. abscessus 
ATCC 19977 strain and the M. abscessus ΔblaMab mutant (Table 1), in correlation with the 
fact that certain antibiotics undergo partial degradation under in vitro testing conditions
45
, led 
us to further investigate the effect of the β-lactam stability on MIC testing procedures. 
 
 
Strains M. abscessus ATCC 19977 M. abscessus ΔblaMab 
Day 3 5 7 12 3 5 7 12 
Antibiotic MIC (mg/L) 
Imipenem 2 4 8 64 1 2 4 64 
Meropenem 8 16 32 256 2 4 4 16 
Cefoxitin 32 32 64 128 32 32 32 128 
Ceftriaxone 64 64 64 64 8 16 16 16 
Ceftazidime >256 >256 >256 >256 256 >256 >256 >256 
Penicillin G >256 >256 >256 >256 2 4 4 4 
Ampicillin >256 >256 >256 >256 4 4 8 8 
Amoxicillin >256 >256 >256 >256 2 4 4 4 
Amikacin 1 2 4 8 1 2 4 8 
*
Broth microdilution method 
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Effect of β-lactam stability on E. coli MIC testing 
In order to experimentally determine whether the results of the M. abscessus MIC testing 
against β-lactams after 3, 5 and 7 days of incubation clearly reflect β-lactamase production or 
are affected by instability of the antibiotics tested, we performed a MIC experiment using E. 
coli XL1-Blue MRF’ model strain, that produces no β-lactamases, against fresh and pre-
incubated (at 37 °C, for 1 to 7 days) β-lactam antibiotics. In that way, all MIC results could be 
obtained after 16 h of incubation of the microtiter plates and putative MIC differences 
between the fresh and the pre-incubated antibiotics could be directly correlated to instability 
of the tested antibiotics. Our results show that pre-incubation at 37 °C affects MIC results of 
imipenem, meropenem and to a lesser extend cefoxitin and ceftazidime (Figure 3a; 3b), 
whereas the MIC results of ceftriaxone, penicillin G, ampicillin, amoxicillin and as expected 
the control stable aminoglycoside antibiotic amikacin, are not influenced by pre-incubation 
(Figure 3b; 3c; 3d). By assuming that drug degradation follows an exponential decay process 
and using the data displayed in Figure 3, we calculated the half-life values of imipenem as 
0,75 day, of meropenem as 1,5 days and of cefoxitin as 3 days. We therefore conclude that the 
increased MIC values of the pre-incubated antibiotics, already before day 3, reflect instability 
of the antibiotics. Reading of M. abscessus MICs at day 3 and later gives a de facto 
misleading impression for the true extend of activity of imipenem, meropenem and cefoxitin.  
 
In vitro antimicrobial stability of cefoxitin, imipenem and meropenem by LC-HRMS  
Based on our results suggesting that incubation of cefoxitin, imipenem and meropenem at 37 
°C gives rise to misleading MIC results, we intended to address the in vitro stability of these 
β-lactams, by quantifying them using LC-HRMS. Tubes containing CAMHB and the 
maximum antibiotic concentration used for AST (256 mg/L) were incubated at 37 °C. The 
100% relative antibiotic concentration of each antibiotic was defined by a day 0 control tube. 
At days 3, 5, 7 and 12 the concentrations of cefoxitin, imipenem and meropenem were 
quantified. Data obtained by LC-HRMS method, clearly show degradation of cefoxitin, 
imipenem and meropenem. Particularly, the relative concentration at day 3 for imipenem 
dramatically dropped to 3.3%, whereas for cefoxitin and meropenem it dropped to 36.6 % and 
35.6 %, respectively (Figure 4e; 4j; 4o). By using the results of this assay, the calculated half-
life of imipenem was 0.6 days, for meropenem 2 days and for cefoxitin 2.1 days. These 
findings agree with those deducted from the E. coli MIC testing and confirm that the MIC 
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values of cefoxitin, imipenem and meropenem against M. abscessus at day 3 and later are 
misleading, as concentration of the active compound is lowered. Especially for imipenem, 
MIC50 at day 3 was 16 mg/L (Figure 4j). However, growth inhibition of half of the clinical 
isolates was in reality achieved by considerably lower drug amounts, as the true active relative 
concentration of imipenem shrank to 3.3% by day 3 due to the short half-life of this antibiotic. 
Consequently, due to instability of imipenem, meropenem and cefoxitin, M. abscessus MIC 
determination after 3 days of incubation does not reflect the potency of these three 
compounds, especially since clinical administration
3 
of these drugs is daily and in multiple 
doses. These data, on the one hand, question the utility of susceptibility testing of imipenem, 
meropenem and cefoxitin, but on the other hand support administration of these parenteral β-
lactam antibiotics as part of combinational regimens for the treatment of M. abscessus 
infections.  
 
 
Figure 3. MIC values of E. coli XL1-Blue MRF’ strain against fresh and pre-incubated (at 37 °C, for 7 to 1 
days) β-lactam antibiotics. (a) Carbapenems: imipenem and meropenem. (b) Cephalosporins: cefoxitin, 
ceftriaxone and ceftazidime. (c) Penicillins: penicillin G, ampicillin and amoxicillin. (d) Aminoglycoside 
(control): amikacin. 
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ECOFF values of cefoxitin, imipenem and meropenem for M. abscessus complex 
According to EUCAST, for the determination of CBP values and improvement of the MIC 
interpretation for clinical isolates, ECOFFs need to be defined to separate the wild-type 
population from any non-wild-type strains with acquired drug resistance mechanisms to the 
chemotherapeutic agents in question.
46
 We, therefore, endeavoured to estimate ECOFF values 
for cefoxitin, imipenem and meropenem by visual inspection of the MIC histographic 
distribution analysis (eyeball method)
36-37
 of 62 M. abscessus complex clinical strains isolated 
from respiratory samples, after 3, 5, 7 and 12 days of incubation at 37 °C (Figure 4). The 
results show that MIC distributions of our collection of M. abscessus complex isolates 
towards cefoxitin, imipenem and meropenem are close to the breakpoints established by CLSI 
and that the eyeball-estimated ECOFF values did not show a separation of the M. abscessus 
complex isolates into two distinct subgroups; wild-type and resistotype. ECOFFs were set at 
the highest MIC value observed among the isolates tested and all of these isolates are 
therefore classified in the wild-type subgroup. According to this classification, a putative 
clinical isolate with an additional β-lactam resistance mechanism would have a very high 
MIC value (higher than the corresponding ECOFF) that would be neither detected by standard 
AST laboratory procedures nor relevant for clinical interpretation. Interestingly, the presence 
or absence of a functional or non-functional β-lactamase in M. abscessus could not be 
predicted by the MIC distribution of the clinical isolates, as the MIC values determined for 
the M. abscessus ΔblaMab (Table 1) fall in the MIC distribution of the “wild-type” subgroup of 
clinical isolates towards all three β-lactams (Figure 4).  
Furthermore, our results show that MIC and MIC50 values of cefoxitin, imipenem and 
meropenem are greatly influenced by incubation time; the longer the incubation period, the 
higher the MIC of the individual strains, the MIC50 and the estimated ECOFF values (Figure 
4). The presented MIC distribution bars, as the MIC50 and ECOFF lines, would represent 
valid data for MIC, MIC50 and ECOFF values, only if the drugs were 100% stable. However, 
according to the LC-HRMS results, cefoxitin, meropenem and particularly imipenem were 
proven as unstable compounds and thereby, MIC values of the M. abscessus complex clinical 
isolates towards these three β-lactams at day 3 and later are certainly overestimated, as 
already discussed. If the concentration of the biological active form of the drug could have 
been kept constant during the AST procedures, we expect that the position of the MIC 
distribution bars, MIC50 and ECOFF lines would be shifted to the left in all MIC distribution 
analysis graphs (Figure 4). Our observations highlight the impact of cefoxitin, imipenem and 
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meropenem stability issues on MIC, MIC50 and ECOFF determination for M. abscessus 
complex clinical isolates.  
 
Figure 4. MIC distributions for cefoxitin (a-d), imipenem (f-i) and meropenem (k-n) for M. abscessus complex 
strains (n = 62). MIC50 values are indicated by a black vertical continuous line, whereas ECOFF values are 
indicated by a black vertical broken line. Symbol “*” shows MIC values of M. abscessus ATCC 19977 type 
strain, while symbol “Δ” shows MIC values of M. abscessus ΔblaMab mutant. Drug stability of cefoxitin (e), 
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imipenem (j) and meropenem (o) in comparison with median MIC50 values. Crosses connected with a black 
continuous line show relative drug concentrations and filled circles connected with a black broken line show 
MIC50 values. 
 
Conclusions 
Taken together, our study confirmed Bla_Mab as the major determinant of innate β-lactam 
resistance in M. abscessus and addressed experimentally the biological effect of β-lactamase 
production and β-lactam stability on M. abscessus MIC testing results after different 
incubation periods. Our results show that MIC, MIC50 and ECOFF values of cefoxitin, 
imipenem and meropenem are immensely influenced by incubation time. LC-HRMS data and 
MIC determination of pre-incubated drugs for the fast growing model organism (E. coli) 
proved significant degradation of cefoxitin, imipenem and meropenem during standard AST 
procedures, explaining the problematic correlation between in vitro susceptibility of these 
three β-lactams and their in vivo activity. Our findings critically question the clinical utility of 
cefoxitin, imipenem and meropenem susceptibility testing, but further support administration 
of these chemotherapeutic agents for treatment of M. abscessus infections. 
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ADDENDUM 
Personal contribution to chapter 3 
My contribution as first author to this manuscript was as follows: 
 Design of the study. 
 Generation of M. abscessus blaMab deletion mutant. 
 Nitrocefin test of M. abscessus blaMab deletion mutant. 
 Drug susceptibility testing of M. abscessus ATCC 19977 and its isogenic blaMab 
deletion mutant. 
 Pre-incubation MIC experiments to study the effect of β-lactam stability on E. coli 
MIC testing 
 Discussion of the results. 
 Writing of the manuscript. 
 Revision of the manuscript. 
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Based on the findings of this study, there are several questions and lines of research arising 
which should be pursued:  
 Design, synthesis and in vitro testing of novel compounds that can escape Arr_Mab-
mediated rifamycin resistance in M. abscessus. 
 
 Study the structural similarities between Arr_Mab and domain III of Pseudomonas 
aeruginosa exotoxin A. Does Arr_Mab play a role in M. abscessus virulence? 
 
 The M. abscessus Δeis1 mutant did not show any phenotype and therefore does not 
contribute to AG resistance, at least not during in vitro growth. Overexpression of 
Eis1, phenotypical analyses and biochemical assays could address the physiological 
and enzymatic function of Eis1.  
 
 Through a biochemical approach, the exact residues of specific aminoglycoside 
antibiotics that Eis2 acetylates could be identified. 
 
 As streptomycin MICs in the mutant strains remained at the high wild-type MIC 
levels, streptomycin resistance mechanisms in M. abscessus should be further studied. 
 
  This study demonstrated that apramycin, arbekacin, isepamicin and kanamycin A 
exhibit excellent in vitro activities against M. abscessus ATCC 19977 type strain and 
that the activity of these drugs is not affected by the AAC(2') and Eis proteins. MIC 
testing of these aminoglycosides against a broader set of M. abscessus clinical isolates 
should be performed. The obtained data may provide invaluable basic knowledge for 
designing clinical trials aiming at implementation of improved treatment regimens 
against M. abscessus. 
 
 Further studies addressing the problematic correlation between in vitro susceptibility 
of imipenem, meropenem and cefoxitin and their in vivo activity should be performed. 
 
 Finally, since genetic manipulation of M. abscessus is now well-advanced, additional 
M. abscessus antibiotic resistance mechanisms, e.g. fluoroquinolones, ethionamide, 
pyrazinamide, could be investigated.  
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